

# Contents

<b>1</b>	<b>Introduction</b>	<b>5</b>
1.1	Cancer Research in the Post-Genomic Era . . . . .	5
1.1.1	Cancer as a Global Health Concern . . . . .	6
1.1.1.1	Genetics and Molecular Biology in Cancers . . . . .	7
1.1.2	The Human Genome Revolution . . . . .	9
1.1.2.1	The First Human Genome Sequence . . . . .	9
1.1.2.2	Impact of Genomics . . . . .	10
1.1.3	Technologies to Enable Genetics Research . . . . .	11
1.1.3.1	DNA Sequencing and Genotyping Technologies . . . . .	11
1.1.3.2	Microarrays and Quantitative Technologies . . . . .	12
1.1.3.3	Massively Parallel “Next Generation” Sequencing . . . . .	13
1.1.3.3.1	Molecular Profiling with Genomics Technology . . . . .	14
1.1.3.3.2	Established Sequencing Technologies . . . . .	15
1.1.3.3.3	Emerging Sequencing Technologies . . . . .	16
1.1.3.4	Bioinformatics as Interdisciplinary Genomic Analysis . . . . .	18
1.1.4	Follow-up Large-Scale Genomics Projects . . . . .	18
1.1.5	Cancer Genomes . . . . .	19
1.1.5.1	The Cancer Genome Atlas Project . . . . .	20
1.1.5.2	The International Cancer Genome Consortium . . . . .	21
1.1.5.2.1	Findings from Cancer Genomes . . . . .	21
1.1.5.2.2	Genomic Comparisons Across Cancer Tissues . . . . .	23
1.1.5.2.3	Cancer Genomic Data Resources . . . . .	24
1.1.6	Genomic Cancer Medicine . . . . .	24
1.1.6.1	Cancer Genes and Driver Mutations . . . . .	25
1.1.6.2	Personalised or Precision Cancer Medicine . . . . .	26
1.1.6.2.1	Molecular Diagnostics and Pan-Cancer Medicine . . . . .	26
1.1.6.3	Targeted Therapeutics and Pharmacogenomics . . . . .	27
1.1.6.3.1	Targeting Oncogenic Driver Mutations . . . . .	27
1.1.6.4	Systems and Network Biology . . . . .	28
1.1.6.4.1	Network Medicine, and Polypharmacology . . . . .	31
1.2	A Synthetic Lethal Approach to Cancer Medicine . . . . .	32
1.2.1	Synthetic Lethal Genetic Interactions . . . . .	32
1.2.2	Synthetic Lethal Concepts in Genetics . . . . .	33
1.2.3	Studies of Synthetic Lethality . . . . .	34
1.2.3.1	Synthetic Lethal Pathways and Networks . . . . .	34

1.2.3.1.1	Conservation and Evolution of Synthetic Lethality	35
1.2.4	Synthetic Lethal Concepts in Cancer . . . . .	36
1.2.5	Clinical Impact of Synthetic Lethality in Cancer . . . . .	37
1.2.6	High-throughput Screening for Synthetic Lethality . . . . .	39
1.2.6.1	Examples of Synthetic Lethal Screens . . . . .	41
1.2.7	Computational Prediction of Synthetic Lethality . . . . .	44
1.2.7.1	Bioinformatics approaches to gene interactions . . . . .	44
1.2.7.2	Comparative genomics . . . . .	45
1.2.7.3	Analysis and modelling of protein data . . . . .	48
1.2.7.4	Differential gene expression . . . . .	50
1.2.7.5	Data mining and machine learning . . . . .	51
1.2.7.6	Bimodality . . . . .	54
1.2.7.7	Rationale for further development . . . . .	54
1.3	E-cadherin as a Synthetic Lethal Target . . . . .	55
1.3.1	The <i>CDH1</i> gene and it's Biological Functions . . . . .	55
1.3.1.1	Cytoskeleton . . . . .	55
1.3.1.2	Extracellular and Tumour Micro-Environment . . . . .	56
1.3.1.3	Cell-Cell Adhesion and Signalling . . . . .	56
1.3.2	<i>CDH1</i> as a Tumour (and Invasion) Suppressor . . . . .	56
1.3.2.1	Breast Cancers and Invasion . . . . .	57
1.3.3	Hereditary Diffuse Gastric Cancer and Lobular Breast Cancer .	57
1.3.4	Somatic Mutations . . . . .	58
1.3.4.1	Mutation Rate . . . . .	58
1.3.4.2	Co-occurring Mutations . . . . .	59
1.3.5	Models of <i>CDH1</i> loss in cell lines . . . . .	60
1.4	Summary and Research Direction of Thesis . . . . .	60
	<b>References</b>	<b>64</b>

# List of Figures

1.1	Synthetic genetic interactions . . . . .	33
1.2	Synthetic lethality in cancer . . . . .	37

# List of Tables

1.1	Methods for Predicting Genetic Interactions . . . . .	44
1.2	Methods for Predicting Synthetic Lethality in Cancer . . . . .	45
1.3	Methods used by Wu <i>et al.</i> (2014) . . . . .	47

# Chapter 1

## Introduction

The thesis presents research into genetic interactions based on genomics data and bioinformatics approaches. This chapter introduces the recent developments in genomics and bioinformatics, particularly in their application to cancer research. Synthetic lethal interactions are a long standing area of research in genetics in both model organisms and cancer biology. Various reasons why these interactions are of interest in fundamental and translational biology will be outlined but first these and similar interactions will be defined. A bioinformatics approach to synthetic lethal interactions enables much wider exploration of the inter-connected nature of genes and proteins within a cancer cell than previous candidate-based approaches. An alternative approach is experimental screening which will be presented and contrasted with bioinformatics approaches in more detail. An emerging application of synthetic lethality is the design of treatments with specificity against loss of function mutations in tumour suppressor genes. E-cadherin (encoded by *CDH1*) is a prime example of this which will be the focus of the analysis in this thesis and as such the role of this gene in cellular and cancer biology will be briefly reviewed.

### 1.1 Cancer Research in the Post-Genomic Era

Genomics technologies have the potential to vastly impact upon various areas including health and cancer medicine. Considering the progress in recent genomics research, it could soon impact greatly upon clinical and wider applications of genetics either directly or by enabling more focused genetics research from candidates selected from genomics or bioinformatics analysis. The completion of the draft Human Genome (Lander *et al.*, 2001) marks a major accomplishment in genetics research and raises

new challenges to utilise this genomic scale information effectively. Technologies in this area have rapidly developed since completion of the human genome project and many global large-scale projects have expanded upon the human genome, to populations (1000 Genomes, 2010), to cancers (Dickson, 1999; Zhang *et al.*, 2011), and to deeper functional understanding (Kawai *et al.*, 2001; ENCODE, 2004). However, impact on the clinic has been slower than initially anticipated following the completion of the “draft” genome with genomics technologies yet to become widely adopted in healthcare and oncology. Here we outline the genomics technologies and bioinformatics approaches which have led to availability of genomics data and techniques used in this thesis and potential for applications in cancer research or the clinic in the future.

### 1.1.1 Cancer as a Global Health Concern

Cancer is a class of diseases involving malignant cellular growth, invasion of tissues, and spread to other organs. While there are also environmental factors, most cancers occur more frequently with age and family history so genetics is widely acknowledged to have an important role in cancer risk. Cancers arise from dysregulated cellular growth or differentiation from stem cells, these can occur through genetic mutations or alterations in gene regulation or expression.

Cancers are a major global health concern, being the second leading cause of death globally (WHO, 2017), with an estimated annual incidence of 14.1 million cases and annual mortality of 8.2 million people (Ferlay *et al.*, 2015). Breast and stomach cancers are among the 5 most frequent cancers globally, with breast cancer affecting women more than other cancer tissue types. Breast cancer has an estimated annual incidence of 1.6 million cases and mortality of 520 thousand people. Stomach cancer has an estimated annual incidence of 950 thousand cases and a mortality of 723 thousand people. Cancer is also a major health concern here in New Zealand, with 19.1 thousand people (including 2.5 thousand cases of breast cancer and 370 cases of stomach cancer) diagnosed annually (Hanna, 2003), among the highest incidence (age-standardised per capita) of cancer in the world (Ferlay *et al.*, 2015).

While the genetic contribution to cancer risk and many of the molecular changes occurring cancers are widely acknowledged (ASCO, 2017; Cancer Research UK, 2017; Cancer Society of NZ, 2017), much of these findings have yet to impact on clinical practice. Diagnostics are traditionally based on pathological examination of cancer cell and tissue samples, including histological staining for biomolecules and biomarkers, and continue to be widely used. The current standard of care is surgery, radiation, and

cytotoxic chemotherapy, depending on whether the cancer is localised or has become systemic (via metastasis) and spread to other organ systems. These approaches are effective against cancers, particularly in patients particular subtypes (such as acute myeloid leukaemia) or early stage cancers. Thus early intervention is important to patient survival and quality of life with national screening programs aiming to diagnose cancers early and subtypes more accurately, including identification of patients with genetic variants or family histories for high risk of particular cancers.

Chemotherapy is a treatment for advanced stage (systemic) cancers which is designed to inhibit the growth and spread of cancer throughout the body by targeting rapidly growing cells. However, this approach is notorious for adverse effects and a narrow therapeutic window and is not suitable for chemopreventative application in many cases (Kaelin, Jr, 2009). Thus high risk individuals are regularly monitored for cancers and offered preventative surgery (Guilford *et al.*, 2010; Scheuer *et al.*, 2002), although this is not completely effective at preventing cancers and may impact on quality of life, depending on the cancer tissue types they are at risk of. Alternative treatment strategies based on molecular biology and other fields are being investigated, including immunological, endocrine, and targeted therapeutics, with a particular interest in treatments with specificity against cancer cells and wider applications (i.e., tolerable effective doses in applications as a chemopreventative or against advanced stage cancers).

#### **1.1.1.1 Genetics and Molecular Biology in Cancers**

Cancers involves dysregulation of genes with both somatic mutations or regulatory disruptions which accumulate during a patient's lifetime and germline mutations which predispose individuals to high-risk early onset cancers (American Cancer Society, 2017; Guilford *et al.*, 1998; NCI, 2015). Cancer is widely viewed to be a genetic disease due to these familial cancer syndromes, hereditary risk factors, and the molecular changes occurring in cancers, including numerous cancer genes which have been identified Stratton *et al.* (2009); Vogelstein *et al.* (2013). Cancer genes are generally classified into two classes: "oncogenes" which are activated in cancers driving tumour growth and invasion or "tumour suppressors" which are inactivated in cancers removing cellular regulation and genomic maintenance functions. The mutations which cause cancers accumulate with age and have been suggested to be inevitably coupled with aging due to the association of cancer incidence with the stem cell divisions in which mutations could occur across tissue types (Tomasetti and Vogelstein, 2015).

Hanahan and Weinberg (2000) identified several key molecular and cellular traits shared across most cancers as a rational approach to the complex change that occurs in cancer initiation and progression due to common molecular machinery underlying all cells. A cancer cell must possess limitless replication potential, modulate growth signals to grow indefinitely, and gain invasive or metastatic capabilities. In addition, cancers must evade apoptosis, the immune system, and sustain angiogenesis and energy metabolism in order to survive (Hanahan and Weinberg, 2000, 2011). In order to achieve this, cancer cells undergo changes to their genomes and the surrounding cells to create a tumour microenvironment. Thus genomic instability has a key role in the survival and proliferation of cancer cells and the progression of further disease, as these malignant characteristics are acquired. Identifying the mechanisms of these acquired traits and the underlying genetic mutation or dysregulation behind them, such as E-cadherin mutation in metastasis or p53 mutation in genomic instability (Hanahan and Weinberg, 2000), will be an important step in understanding and inhibiting cancer with the next generation of genomically-informed treatments.

Molecular biological processes have particular importance in characterising breast cancers. Gene expression and regulatory signals confer cell identity and response to the environment. Therefore gene expression has been investigated with microarray technologies Perou *et al.* (2000), with “intrinsic subtypes” identified characterised by estrogen receptor, *HER2*, and basal, epithelial signaling. The expression profiles were similar across independent samples of the same tumour and between primary and metastatic tumours of the same patient. Thus expression profiles represent the molecular state of a tumour rather than the sample and the molecular configuration of the cells regulation is carried through the cellular lineage of during metastasis preserving the molecular subtype. These molecular intrinsic subtypes “luminal A”, “luminal B”, “HER2-enriched”, “basal-like”, and “normal-like” have been replicated across microarray studies (Hu *et al.*, 2006), with their relevance to prognosis (including predicting survival and response to neoadjuvant chemotherapy) demonstrated and a 50-gene subtype predictor from microarray and qPCR analysis has been provided (Parker *et al.*, 2009; Sørlie *et al.*, 2001). This has been further updated with the “claudin-low” subtype (Herschkowitz *et al.*, 2007) and stimulated further investigations into subtyping of breast cancers by molecular properties. Despite differences in subtyping performed by different research groups and companies, there is widespread agreement that distinguishing luminal, HER2-enriched, and triple negative tumours can be performed with expression profiles and have value in our understanding of cancer progression and



prognostic importance for patients Dai *et al.* (2015). High-throughput technologies have the potential to enable such subtyping on a vast scale in discovery of further subtypes in breast cancer or other diseases and in identification of these subtypes along with mutations in routine clinical diagnostic and prognostic testing. The “Pan cancer” approaches by the cancer genome atlas project (as discussed in more detail in section 1.1.5.2.1) expand on the importance of molecular differences between cancers by examining molecular profiles across cancer tissue types (Weinstein *et al.*, 2013).

Cancer is a major health concern with a well-established genetic contribution, in risk and in the molecular changes occurring during progression (Stratton *et al.*, 2009). Many genes have been discovered to be important in different cancers with molecular differences between cancers, including alterations across the genome, being of clinical importance. As such cancers were among the first samples investigated with genomics following the sequencing of the human genome Dickson (1999) and continue to be the subject of genomics and bioinformatics investigations.

## **1.1.2 The Human Genome Revolution**

The advent of the Human Genome sequence (Lander *et al.*, 2001) has transformed genetics research including the study of health and disease (Lander, 2011; Peltonen and McKusick, 2001). Systematic, unbiased studies across all of the genes in the genome are viable in unprecedented ways. The successful undertaking of such an international scientific megaproject has set an example for numerous initiatives to follow, including many genomics investigations expanding to species, to the functional, or to the population level (Collins *et al.*, 2003). These projects serve as an excellent resource for genetics research globally, particularly for cancers where genomics investigation have been widely applied to different tissues across molecular profiles Bamford *et al.* (2004); Weinstein *et al.* (2013); Zhang *et al.* (2011). Genome sequencing technologies continue to improve, drop in price, and become feasible in more research and for clinical applications.

### **1.1.2.1 The First Human Genome Sequence**

The first human genome is a good example of a large-scale genomics project for its success as an international collaboration and releasing their data as a resource for the wider scientific community (Collins *et al.*, 2003; Lander *et al.*, 2001). This particular project generated significant public interest due to it being a landmark achievement,

the first of its scale, and some controversial findings. Namely, the number of genes discovered (particularly those specific to vertebrates) was much lower than most estimates of a genome of its size and the number of repetitive transposon elements was very high. Even the figure of 30–40,000 genes given by the original publication is now regarded to be an overestimate (Ezkurdia *et al.*, 2014; IHGSC, 2004).

Accounting for the “complexity” encoded by the human genome with so few genes has led to investigations into molecular function, expression profiling, and population variation. When announcing the draft genome, Lander *et al.* (2001) concede that genomic information alone is not sufficient for biological understanding and that many investigations remain to be done, with their objective being to share the raw genome data so that it was available for further inquiry rather than interpreting it themselves. While genomics technologies and genomics projects have flourished since then, the need in turn for systematic means of interpreting data of such scale and for the interdisciplinary expertise to do so has only grown.

The “whole genome shotgun” approach (now widely used in genomics sequencing) was pioneered by a competing private genome project completed shortly afterwards by Celera Genomics, demonstrating the power and speed of this approach by sequencing 27 million reads of the entire 2.91Gbp human genome ( $5.11\times$  coverage) in only 9-months (Venter *et al.*, 2001). Assembly was assisted with the  $2.9\times$  coverage public genome data, reduced to raw shotgun reads to remove cloning bias. While, repetitive sequences remained an issue for this project, more than 90% of the genome was able to be assembled into 100kbp scaffolds and 26,588 protein coding genes were identified, closer to the current consensus for the number of genes in the human genome. This project in particular emphasised the value of computational assembly methods in handling a large number of reads, reducing the time and cost of sequencing, and established the shotgun approach for wider adoption with more recent sequencing technologies with shorter reads.

### **1.1.2.2 Impact of Genomics**

Genomics has stimulated investigations into many of these previously largely explored areas of functional genetics and thus been of immense value in genetics research, attracting high expectations for further applications. Genomics research has become anticipated for its potential for widespread applications in healthcare, agriculture, ecology, conservation, and evolutionary biology, although many of these are yet to come to fruition.

Cancer research is an area of particularly high expectations for the clinical impact of genomics in oncology. Genomics technologies have potential applications across cancer diagnostics, prognosis, management, and developing treatment. Cancers are often involve genetic mutation or dysregulated gene expression which can be detected in a genome or transcriptome with potential to improve patient care. While direct impact of genomics on the clinic has been limited, compared to initial expectations following the publication of the human genome, diagnostic cancer genes and therapeutic targets identified with genomics research have begun to be introduced in the clinic (Stratton *et al.*, 2009).

### **1.1.3 Technologies to Enable Genetics Research**

#### **1.1.3.1 DNA Sequencing and Genotyping Technologies**

Genotyping was once commonly performed on variable regions of the genome with restriction fragment length polymorphisms (RFLP) or repetitious microsatellite regions. These exploited sequence variation at target sites of restriction enzymes or measured the length of repetitious regions, using polymerase chain reaction (PCR), restriction enzymes, and gel electrophoresis to measure DNA genotypes at particular sites. This is laborious and limited to well characterised variable regions of the genome, generally genes or nearby marker regions.

The Sanger (dideoxy) chain termination method (Sanger and Coulson, 1975) enabled DNA sequencing and genotyping at a widespread scale, being less technically difficult than the Maxam-Gilbert sequencing by degradation method (Gilbert and Maxam, 1973; Maxam and Gilbert, 1977), which required more radioactive and toxic reactants. The Sanger methodology has relatively long read length (particularly compared to early versions of more recent technologies), with read lengths of 500–700 base pairs accurately sequenced in most applications, usually following targeted amplification with PCR. Sanger sequencing by gel electrophoresis takes around 6–8 hours and has been further refined with the “capillary” approach to 1–3 hours and requiring less input DNA and reactants. The capillary approach has been scaled up to run in parallel from a 96 well plate, at 166 kilobases per hour. The 96 well parallel capillary method was one of the main innovations which made the first Human Genome Project feasible and was used throughout (Lander *et al.*, 2001). Due to the quality of the Sanger sequence reads and low cost, it is still widely used in smaller scale applications, clinical testing, and to validate the findings of newer approaches.

### 1.1.3.2 Microarrays and Quantitative Technologies

Real-time or quantitative PCR (qPCR) is another adaptation of genetic technologies to quantitatively study nucleic acids, often reverse transcribed “cDNA” or messenger “mRNA” to measure (relative) gene expression or transcript abundance. While numerous quality control measures are required to correctly interpret a qPCR experiment, these have similarly become widely adopted as are still used for smaller scale experiments and as a “gold standard” for measuring gene expression (Adamski *et al.*, 2014). This also represents a shift in the application of PCR and sequencing technology, where the primary interest is quantifying the amount of input material (by the rate of amplification to a certain level) rather than the qualitative nature of the sequence itself. The more recent technologies of microarrays and RNA-Seq have similarly embraced this application to quantify DNA copy number, RNA expression, and DNA methylation levels. Due to results of comparable or arguably better quality from these newer technologies (Beck *et al.*, 2016; Git *et al.*, 2010; McCourt *et al.*, 2013; Robin *et al.*, 2016), this “gold standard” status has started to come under scrutiny.

Microarrays represent a truly high-throughput molecular technique, reducing the cost, time, and labour required to study molecular factors such as genotype, expression, or methylation across many genes, making it feasible to do so over a statistically meaningful number of samples. Microarrays are manufactured with probes which measure binding of particular nucleotide sequences to either quantitatively detect the presence of a sequence such as a single nucleotide polymorphism (SNP) or quantify DNA copy number, gene expression, or DNA CpG methylation. Microarray technologies have popularised “genome scale” studies of genetic variation and expression.

In addition to being more versatile and higher-throughput than PCR based techniques, microarrays are considered cost-effective, particularly when scaled up to large number of probes. They are also available with established gene panels or customised probes from a number of commercial manufacturers. These remained popular during the introduction of newer technologies due to reliability and this relatively lower cost, especially in large-scale projects involving many samples. However, microarrays have issues with signal-to-noise ratio, with both sensitivity to low nucleic acid abundance and “saturation” of probes at high abundance, edge effects, and requiring more starting material than qPCR. Thus qPCR is still used for many small gene panel studies.

### 1.1.3.3 Massively Parallel “Next Generation” Sequencing

Similar to microarrays, the introduction massively parallel sequencing technologies have further expanded the availability of high-throughput molecular studies to researchers, with corresponding availability of genomics data from these studies. This “Next Generation Sequencing” (NGS) expands not only gene expression studies (compared to microarrays) but extends to genome sequencing *de novo* for previously unknown genome and transcriptome sequences at an unprecedented scale. This has been a particularly important technological revolution in genomics, as the cost and time of genome sequencing has dropped dramatically and enabled sequencing projects of far more samples and applications beyond the Human Genome Project. Particularly, when dealing with variants in a species with an existing reference sequence such as humans, where the computational cost of mapping to a reference over a genome assembly. However, the cost of sequencing (RNA-Seq) for gene expression or DNA methylation studies is still considerably higher than a microarray study (limiting feasible sample sizes).

Compared with arrays, NGS studies have additional challenges, particularly with large data and compute requirements to handle the raw output data. Compared the established methods to analyse microarray data, handling NGS data can be more technically difficult. While methods developed for analysing microarray data can be repurposed for sequence analysis in many cases, more bioinformatics expertise is required particularly to handle the raw read data and changing approaches for various changes in sequencing technologies. One of the main computational challenges is the assembly reads or mapping to a reference genome due to the inherently small reads of most NGS technologies compared to the Sanger methodology. Furthermore, there are fewer software releases and best practices established specifically RNA-Seq data, thus many analyses are still conducted with customised analysis approaches and command-line tools. Compared to existing graphical tools or pipelines for microarray analysis, this is a more active technology for bioinformatics research with many applications of genomics data have yet to be explored.

However, the methodology itself has challenges with the sample preparation, requiring a relatively high quantity of input material and “contamination” with over abundant ribosomal rRNA taking up the majority of the sequencing if not purified correctly. This abundance of rRNA is a particularly important issue in microarray and RNA experiments in Eukaryotes where it is commonplace target the mRNA by binding to the poly-A tail (RNA-Seq) or 5’ cap (CAGE-Seq). However, this has the potential to exclude microRNAs (miRNA) and long non-coding RNAs (lncRNA) of interest unless

the sample is prepared specifically to study these. Similarly capturing a subsection of the genome for exome analysis or reduced representation bisulfite sequencing (RRBS), focuses on sequencing DNA sequences and methylation levels of CpG sites near known genes to reduce cost, noise, and incidental findings.

In many cases, the benefits of NGS technologies over microarrays still outweigh the additional cost. NGS technologies have the advantage of greater potential accuracy and sensitivity than microarrays, depending on the sequencing depth or “coverage”, theoretically sensitive down to the exact number of molecules for each transcript. NGS experiments are regarded as “reproducible” with no need for technical replicates, although these are still performed for a subset of samples in many projects for quality assurance purposes. NGS has a wider dynamic range than microarrays and is able to detect SNPS, InDels, and splice variants in addition to quantifying DNA copy number or transcript abundance. NGS scales to all genes and beyond for these molecular applications without having to design new probes as required for a microarray. Thus NGS technologies are not limited to genes already characterised sequence or functions, do not need to be updated with new probes for each genome annotation release, and do not require a reference genome at all for new species. A “transcriptome” can be assembled *de novo* for an expression study in any organism by sequencing the mRNA extracted from a cell.

#### **1.1.3.3.1 Molecular Profiling with Genomics Technology**

NGS is highly adaptable to different applications: DNA sequencing (whole genome or exome), DNA methylation (bisulfite-Seq), RNA-Seq, miRNAs, lncRNA, or chromatin immunoprecipitation (CHIP-Seq). Employing RNA-Seq to the transcriptome are a common adaptation, RNAs is reverse transcribed and sequenced from the resulting complementary “cDNA”. This is utilised to be quantify the levels of RNA and identify which regions of DNA are expressed. Similar bisulfite treatment converts cytosine residues to uracil (sequenced as thymidine), sparing methylated cytosine enabling it to be distinguished with bisulfite-Seq for high-throughput detection of the notable epigenetic mark and is a common procedure to generate an epigenome. Subsets of the nucleic acid may be extracted for sequencing such the coding regions of DNA (for the “exome”), the mRNA 5’cap (CAGE-Seq), mRNA 3’poly-A tail (RNA-Seq), microRNA, or an enriched subset of variable regions for DNA sequencing (“genotyping by sequencing”) and methylation studies (“reduced-representation bisulfite sequencing”). High-throughput gel and mass spectrometry techniques have been employed to pro-

teins and metabolites to generate the proteome and metabolome respectively. These “omics” technologies are applicable across a wide range of biomolecules in a cell and these “molecular profiles” are produced in many experimental laboratories.

### 1.1.3.3.2 Established Sequencing Technologies

454 sequencing (acquired by Roche) commercially released from 2005 to 2013 was the first NGS technology, generating a vast 1 million reads per day or 400–600Mbp in a 10 hour run. This technology used the “pyrosequencing” method of sequencing by synthesis, detecting phosphates released when a compatible nucleotide reacts and extends the DNA synthesis of a complementary strand. This technology popularised NGS with the first complete genome from a single individual (Wadman and Watson, 2008; Wheeler *et al.*, 2008) and Neanderthal ancient DNA studies (Green *et al.*, 2009; Noonan *et al.*, 2006). While this technology was capable of reads up to 1kb, reads of 400–500bp were more typical and the technology had difficulties with accurately processing runs of repeated bases (Rothberg and Leamon, 2008). These are still relatively long reads for an NGS technology but it has been discontinued due to competing short read technologies being more cost-effective with lower running costs.

SOLiD sequencing (acquired by Life Technologies and then Thermo Fisher) released in 2006 employed a vastly different approach to NGS, using labelled dinucleotide pairs for “sequencing by ligation” to produce a highly accurate sequence (99.94%) with built-in error correction by sequencing two reading frames and is unaffected by consecutive bases. This technology is also high-throughput, producing 1200–1400 million reads (66–120Gbp) in a 7–14 day run (ThermoFisher, 2017b). However, SOLiD sequencing does not cope well with palindromic sequences and SOLiD reads are very short only 35bp, making it more difficult to assemble them.

Illumina sequencing (developed by Solexa and later acquired by Illumina) was also released in 2006. It utilises reversible terminating dyes to sequence by synthesis with a lower accuracy (98%) and read lengths of 150–250bp. Illumina more than makes up for relatively short reads (along with improving the read length of the technology) and low accuracy with high-throughput and cost effectiveness, with a Hi-Seq 4000 platform producing up to 10 billion paired-end reads (1500Gbp) in a run of appropriately 3 days, capable of sequencing 12 human genomes (30× coverage) or 100 human transcriptomes simultaneously (Illumina, 2017). Illumina has further reduced the cost of sequencing with the economies of scale with the Hi-Seq X 10 claiming to produce a human genome (with 30× coverage) for less than US\$1000, the first platform to achieve this long-

standing goal in genomics. The high-throughput of Illumina sequencing also makes deep sequencing for high coverage, high quality consensus reads, and sensitive RNA-Seq experiments feasible. Illumina sequencing now has a dominating market share of the NGS technologies.

### 1.1.3.3.3 Emerging Sequencing Technologies

Ion Torrent (also acquired by Life Technologies) released in 2010 employs “sequencing by synthesis” but in a drastically different way with ion semiconductor sequencing, detecting  $H^+$  ions released when bases during DNA synthesis. Without the use of optical detection, the Ion Torrent system is compact offering rapid, cost-effective sequencing with the potential to scale with the future development of silicon semiconductors with have historically doubled in density every 2 years (Moore’s Law). It is capable of reads of 100–200bp in only an hour (as fast as 4 seconds per base) and up to 400bp in a 2 hour run with an accuracy of 99.6% (dropping to 98% for consecutive sequences of 5 bases). While fast, cost effective, and accurate, Ion Torrent has short reads and modest throughput (up to 10 Gp for the Ion Proton and 15 Gb for the Ion S5 XL systems) compared to other sequencing technologies (ThermoFisher, 2017a).

Pacific Biosciences (PacBio) released the RS and RS II platforms in 2010 and 2011 to make up for the short reads in NGS technologies with the single molecule real time (SMRT) approach capable of long read lengths, averaging between 2.5–7kb and up to 80kb PacBio (2017). The PacBio methology traps each molecule in a zero mode waveguide (ZMW) and sequences it in real time. The RS II has 150,000 ZMW and an output of 500Mbp–1Gbp per SMRT cell (doubling that of the RS), with the capacity to run up to 16 concurrently for 0.5–6 hours. While the single molecule sequencing approach has strengths in sensitivity and potential to detect 3D structures, such as G-quadruplexes, this has the drawback of slowing down the sequencing and reducing the throughput of the platform. Another issue is sequence quality with the raw data as poor as 20–30%. However, PacBio recommends specific software to assemble as consensus with 99.999% for sequences with over  $20\times$  coverage, regardless of sequence repeats or GC composition. Despite concerns over data quality and higher cost than other approaches, the long reads are appealing for genome assembly and in many genome studies combine PacBio reads with more accurate short read technologies. However, due to the poor separate quality of reads this technology may not be appropriate for RNA-Seq studies, while it does have the potential for high sensitivity and detecting alternative splicing were it be improved. PacBio has recently released the Sequel (2016)



system, increasing the throughput of the SMRT Cells  $7\times$  to 1 million ZMW holes with an output of 5–10Gb for each of 16 SMRT cells.

Nanopore sequencing is another technology capable of long reads in real time and direct single molecule sequencing, avoiding amplification bias, detecting modified bases and directly sequencing RNA molecules. This also reduces laboratory preparation times. Nanopores work by measuring the ion current through a pore in a electrically insulating membrane as a nucleic moves through it. Oxford Nanopore has been developing this technology since 2005, launching the MinION in 2014 which employs biological nanopores: a transmembrane protein through which DNA or RNA passes, blocking ion current differently for each base. Each pore sequences in real time, capable of sequencing 450bp per second (Nanopore, 2017). However, there are quality issues with each individual read with quality estimates varying between 87–98%, with improvements to the quality of detection accounting for significant delays in the release of this technology. The MinION makes up for this is a capacity for extremely long reads, averaging 5.4kbp (Hayden, 2014) up to a maximum of 200Kbp and being a portable platform with very few overhead costs. While the MinION is limited in scale with only one flow cell of 512 pores (5–10Gbp), the PromethION being released in early access in 2016 scales this technology with flow cells of 3000 pores and the capacity to run 48 (up to 4 samples each) in parallel for 144,000 long reads with a versatile, modular system including built-in computing resources. One of the main issues with Oxford Nanopore systems is accuracy, with the manufacturer suggesting the use of consensus sequences for higher accuracy as PacBio does. The main source of this pore accuracy is the width of biological pores resulting in several bases being in the pore at any one time, inferring the sequence from the ion currents of each respective combination of bases and distinguishing them is a major technical challenge.

Quantum Biosystems in Japan is developing a synthetic nanopore system to address this issue. While the technology is still in development, it has the potential to produce similarly long reads, with a high-throughput, low running cost, and rapid run time (Quantum Biosystems, 2017). The technical challenges to develop a nanotechnology capable of this are immense but such developments serve as but one of example of how sequencing technologies may continue to improve, becoming more feasible for a wider variety of applications.

Due to such benefits of sequencing over previous technologies (and their continued refinement), this thesis has focused on gene expression data generated by RNA-Seq rather than by microarrays. RNA-Seq data is widely available as a resource from large-scale

cancer genomics projects and methods to make inferences from RNA-Seq experiments could feasibly be applied to many other studies based on these current (or similar future) technologies.

#### **1.1.3.4 Bioinformatics as Interdisciplinary Genomic Analysis**

Genomics technologies have given rise to data at a scale previously rarely encountered in molecular biology, making inference with conventional techniques difficult. Computational, Mathematical, and Statistical skills are required to handle this data effectively, in addition to biological background to frame and interpret research questions. Drawing upon these disciplines to handle biological data has become the field of “Bioinformatics”, focusing specifically on making inferences from genomics and high-throughput molecular data or developing the tools to do so. This contrasts with the existing fields of “theoretical” or “computational biology” which existed prior to genomics data, focusing on modelling and simulating aspects of biology without necessarily addressing the genomics data or detecting the phenomena in nature, extending beyond genetics to cell modelling, neuroscience, cancer development, ecology, and evolution.

In practice, many researchers identify with both bioinformatics and computational biology, or draw upon the findings and methods of the other field. This thesis uses many approaches in bioinformatics to biological research questions and established mathematical or bioinformatics resources.

Gene expression analysis is the focus of many bioinformatics research groups, drawing upon statistical approaches to appropriately handle microarray and RNA-Seq data along with making biological inferences from a large number of statistical tests. This presents various challenges from normalising sample data and accounting for batch effects to developing or applying statistical tests tailored to biological hypotheses and testing them at a genome-wide scale, generally across thousands of genes. There are numerous approaches for dealing with these challenges, some of which will be described in chapter 2.

#### **1.1.4 Follow-up Large-Scale Genomics Projects**

A number of projects have attempted to follow up on the human genome project to varying degrees of success. The genomes have since been sequenced for a variety of model organisms, organisms of importance in health, agriculture, metagenomics of microorganisms (microbiome), ecology and conservation. Genomics projects have also

been applied functional genetics (Kawai *et al.*, 2001; ENCODE, 2004) and to human populations with an interest variability between individuals and health or disease risk (HapMap, 2003; 1000 Genomes, 2010).

Other genomics databases have focused on facilitating distribution of genomic data generated by researchers, rather than generating it themselves. Genbank (NCBI) in the US, EMBL in Europe, and the DDBJ (NIG) in Japan do so by serving as repositories of DNA sequence data. GEO (Clough and Barrett, 2016), arrayExpress (Rustici *et al.*, 2013), and caArray (Heiskanen *et al.*, 2014) serve a similar purpose as a resource for gene expression datasets, originally developed for microarray data but RNA-Seq data is now supported by some platforms. They are repositories for researchers to deposit, share, and access gene expression data, which serve as a resource to support ongoing research to utilise data for genes of interest to particular research groups and further to make inferences based on larger datasets than accessible to any individual laboratory (Rung and Brazma, 2013). These resources cover not only DNA sequence across the genome but also molecular profiles of other factors by adapting genomic sequencing or other high throughput technologies for quantifying gene expression or DNA methylation. Sharing the expression datasets generated in a publication is now required by some journals.

Similarly, international projects and consortiums have begun to release data gathered using common agreed upon protocols in laboratories across the world, often hosting public databases of these themselves, publishing their own investigations into the datasets as they are released, or offering basic searches and analytics of the data via a web portal. These databases include many of the genomics projects discussed above and the cancer-specific projects discussed below. In many ways, the quality, consistency, and accessibility of these international projects has become more appealing than accessing smaller studies, particularly for gene expression datasets where the more recent, larger projects have switched from microarray to RNA-Seq technologies. This distinction will also be discussed later.

### 1.1.5 Cancer Genomes

It's importance in the future of cancer research was noticed, even in the early days of genomics (Dickson, 1999). The Cancer Genome Project (CGP) based at Wellcome Trust Sanger Institute in the UK were among the first to launch investigations into cancer after the publication of the Human Genome, using this genome sequence, consensus across the cancer reserach literature, and sequencing the genes of cancers themselves.

Initially, the Sanger Institute set out to sequence 20 genes across 378 samples while the Human Genome project was still ongoing (Collins and Barker, 2007), optimising sequencing and computation infrastructure for a larger project while doing so. The main aim of the Cancer Genome Project was to discover “cancer genes”, those frequently mutated in cancers by comparing the genes of cancer and normal tissue samples, both “oncogenes” and “tumour suppressors” which are activated and inactivated respectively in cancers. This project is ongoing and the UK continues to be involved in international sequencing initiatives and those focused on particular tissue types.

The Sanger Institute also hosts the Catalogue of Somatic Mutations in Cancer (COSMIC, 2016), a database and website of cancer genes. This launched with 66,634 samples and 10,647 mutations from initial investigations into *BRAF*, *HRAS*, *KRAS2*, and *NRAS* (Bamford *et al.*, 2004). It has since expanded to include 1,257,487 samples with 4,175,8787 gene mutations curated from 23,870 publications, including 29,112 whole genomes (COSMIC, 2016). This database now also identifies cancer genes from DNA copy number, differential gene expression and differential DNA methylation.

#### 1.1.5.1 The Cancer Genome Atlas Project

Based in the US, the Cancer Genome Atlas (TCGA) project was established in 2005, a combined effort of the National Cancer Institute (NCI) and the National Human Genome Research Institute (NHGRI) of the National Institutes of Health (NIH) (TCGA, 2017). They first set out to demonstrate the pilot project on brain (McLendon *et al.*, 2008), ovarian (Bell *et al.*, 2011), and squamous cell lung (Hammerman *et al.*, 2012) cancers. In 2009, the project expanded aiming to analyse 500 samples each for 20-25 tumour tissue types. They have since exceeded that goal, with data available for 33 cancer types including 10 “rare” cancers, a total of over 10,000 samples.

The TCGA projects set out to generate a molecular “profile” of the tumour (and some matched normal tissue) samples: the genotype, somatic mutations, gene expression, DNA copy number, and RNA methylation levels. While these were originally performed largely with microarray technologies, exome and RNA-Seq has been since adopted and performed for many TCGA samples, with whole genomes being performed for some samples. Data which cannot be used to identify the patients (such as somatic mutation, expression, methylation, and various clinical factors) are publicly available.

### 1.1.5.2 The International Cancer Genome Consortium

TCGA and the Cancer Genome project in the UK are part of a larger International Cancer Genome Consortium (ICGC), now a concerted effort across 16 countries to sequence the genome, transcriptome, and epigenome of 50 tumour types from over 25,000 samples total (Zhang *et al.*, 2011). With some redundancy the following countries are profiling various tumour types: USA (including TCGA), China (16), France (10), Australia (4), South Korea (4), the UK (4), Germany (4), Canada (3), Japan (3), Mexico (3 in collaboration with the US), Singapore (2), Brazil, India, Italy, Saudi Arabia, and Spain. This is inherently international and several projects are collaborations, such as between the USA and Mexico, Australia and Canada, Singapore and Japan, along with the UK and France representing the European Union (ICGC, 2017). In order to avoid competing the existing TCGA projects, some countries focus on a particular cancer they have health interest: Australia (melanoma), Brazil (melanoma), India (oral), Saudi Arabia (thyroid), and Spain (CML). Others focus on a particular tissue subtype with poor prognosis: The UK (triple negative or Her2+ breast cancer), France (clear cell kidney), Australia and Canada (ductal Pancreas). Another approach is to focus on rare or child cancers: Canada, Italy, France, Germany, Japan and Singapore, and the US (TARGET project). Particularly countries in Asia (China, Japan, Singapore, and South Korea) have emphasised the value of adding tumour data from non-Western countries or non-European populations in addition the data from Europe and the TCGA in the US. Data from 9 of these countries is already available on the ICGC website with the project ongoing.

#### 1.1.5.2.1 Findings from Cancer Genomes

The cancer genome atlas pilot projects (Bell *et al.*, 2011; Hammerman *et al.*, 2012; McLendon *et al.*, 2008) serve to demonstrate the power of applying genomics technologies to cancer research at such as scale. In addition to sequence the whole genome or a subset (exome), DNA copy number, gene expression, DNA methylation, and somatic mutations were also analysed. The initial projects used microarray technologies for expression and methylation data but these have since been replaced by RNA-Seq for expression. TCGA demonstrated the potential discovery of the molecular basis of cancer by analysing 206 glioblastoma brain cancer samples (McLendon *et al.*, 2008), highlighting the roles of *ERBB2*, *NF1*, *TP53*, and *PIK3R1* mutations, along with altered methylation of *MGMT*, and the core pathways of RTK, p53, and RB signaling

in brain cancer. An analysis of 489 serious ovarian cancers (Bell *et al.*, 2011) similarly reported *TP53* mutations specifically over-represented in high grade tumours and reported 133 copy number variants, 168 differentially methylated regions, and recurrently somatic mutations in 9 genes in low grade tumours including *NF1*, *BRCA1*, *BRCA1*, *RB1*, and *CDK12*. Four transcriptional subtypes of ovarian cancers were identified, alterations in *BRCA1*, *BRCA2*, and *CCLE* had an impact of patient survival, and the homologous recombination, NOTCH and FOXM1 signaling pathways were involved in ovarian cancer growth. The genomics of 178 squamous cell lung cancers (Hammerman *et al.*, 2012) were highly complex, averaging at 360 mutations in coding regions. While no targeted therapies existed for this cancer subtype, 11 recurrently mutated genes were identified including *TP53* and *HLA-A*. The pathways altered in various squamous cell lung cancers were NFE2L2, KEAP1, differentiation genes, PI3K, CDKN2A and RB1. These aberrant genes and pathways represent potential therapeutic targets which could be identified for most samples.

The TCGA breast cancer analysis (TCGA, 2012) consisted of 802 samples with exomes, copy number variants, RPPA protein quantification, and DNA methylation, mRNA, and microRNA arrays with 97 whole genomes sequenced. Four main molecular classes were identified to subtype the samples, despite considerable heterogeneity between samples. Recurrent mutations across more than 10% of samples were identified in *TP53*, *PIK3CA*, and *GATA*. TCGA further suggests subtypes by HER2 and EGFR protein levels. In a further analysis of 817 breast cancer samples including 127 invasive lobular breast and 88 mixed type samples (Ciriello *et al.*, 2015), 3 molecular subtypes of lobular breast cancer were identified. Lobular breast cancer was also characterised by recurrent mutations in *CDH1*, *PTEN*, *TBX2*, and *FOXA1* /

TCGA reported results of colon and rectal cancers in a combined analysis of 267 samples (Muzny *et al.*, 2012), finding no genomic distinction between colorectal cancers. Apart from 16% of hypermutated colorectal cancers, the remaining samples were very similar at the molecular level with 24 significantly recurrently mutated genes identified. These include the expected *APC*, *TP53*, *SMAD4*, *PIK3CA*, and *KRAS* genes. Additionally, novel recurrent mutations were identified in *ARID1A*, *SOX9*, and *FAM123* along with recurrent copy number alterations in *ERBB2* and *IFG2*. Thus the molecular findings of colon and rectal tumours can be applicable across colorectal cancers, including the known characteristics of microsatellite instability (MSI) and CpG island methylator phenotype (CIMP) found in some colorectal tumours.

The TCGA stomach cancer analysis of 295 samples (Bass *et al.*, 2014) identified 4

molecular subtypes of stomach cancers characterised by: the Epstein-Barr virus, MSI, genomics instability, and chromosomal instability. Aberrations in *PD-L1*, *PIK3CA*, and *JAK2* were also identified in stomach cancers which may present therapeutic targets.

#### 1.1.5.2.2 Genomic Comparisons Across Cancer Tissues

TCGA have identified various genes as recurrent, driver mutations across cancer types which are likely to have a role in driving the proliferation of these cancers and present a molecular target that could be applied across tissue types. These include *TP53* (in brain, lung/head/neck squamous cell, breast, colorectal, uterine, and endometrial cancers), *ERBB2/HER2/NEU* (in brain, breast, colorectal, bladder, and lung cancers), *PIK3CA*, *PIK3R1* (in brain, breast, colorectal, endometrial, bladder, clear cell renal, and lung cancers), *BRCA1/BRCA2* (in breast and ovarian cancers), *NF1* (in brain, ovarian, and skin cancers), *ARID1A* (in colorectal, endometrial, and clear cell renal cancers), *KRAS* (in colorectal, endometrial, and skin cancers), *BRAF* (in colorectal, thyroid, and skin cancers), *EGFR* (in brain, breast, and lung cancers), and *PTEN* (in breast, endometrial, and uterine cancers) (Agrawal *et al.*, 2014; Akbani *et al.*, 2015; Bass *et al.*, 2014; Bell *et al.*, 2011; Burk *et al.*, 2017; Cherniack *et al.*, 2017; Ciriello *et al.*, 2015; Collisson *et al.*, 2014; Creighton *et al.*, 2013; Hammerman *et al.*, 2012; Kandoth *et al.*, 2013; Lawrence *et al.*, 2015; McLendon *et al.*, 2008; Muzny *et al.*, 2012; TCGA, 2012; Weinstein *et al.*, 2014). In addition to disregarding the distinct between colon and rectal cancers based on molecular similarity (Muzny *et al.*, 2012), the TCGA project have observed differences within tumour types and proposed molecular subtyping for breast, clear cell renal, papillary renal, stomach, skin, bladder, and prostate cancers (Abeshouse *et al.*, 2015; Akbani *et al.*, 2015; Bass *et al.*, 2014; Ciriello *et al.*, 2015; Creighton *et al.*, 2013; Hammerman *et al.*, 2012; Linehan *et al.*, 2016; Muzny *et al.*, 2012; TCGA, 2012; Weinstein *et al.*, 2014).

The “Pan cancer” project (Hoadley *et al.*, 2014; Weinstein *et al.*, 2013) analysed 3527 samples across 12 tissue types for DNA, RNA, protein, and epigenetic molecular profiles. This project was initiated in 2012 to perform a comprehensive analysis of molecular data across cancer types to identify molecular similarities and differences. Recurrent *TP53* mutations characterised high grade tumours across breast, ovarian, and endometrial cancers. HER2 was identified in brain, endometrial, bladder, and lung cancers, in addition to the known role of HER2 in breast cancers. *BRCA1* and *BRCA2* mutations were also detected across cancers, mainly breast and ovarian cancers

as expected. Microsatellite instability characterised both endometrial and colorectal cancers. The Pan cancer project (Hoadley *et al.*, 2014) has identified 11 molecular subtypes across these tissues, 5 of corresponding to tissue cancer types and the remainder reassigned due to molecular similarities shared across cancer types. Squamous cell lung, head, and neck and a subset bladder cancers were grouped together by molecular similarities, characterised by a high frequency of *TP53* mutations. Conversely, bladder cancers were divided into 3 of these molecular subtypes with distinct profiles. This project further supports the genomic stratification of patients, demonstrated in breast cancer (Parker *et al.*, 2009; Pereira *et al.*, 2016; Perou *et al.*, 2000), which may apply to other cancer types and to molecular characteristics across them targeting recurrent mechanisms of cancer growth and progression (Hanahan and Weinberg, 2000, 2011).

### 1.1.5.2.3 Cancer Genomic Data Resouces

While the findings from the TCGA projects themselves are a considerable contribution to understanding cancer biology within and across tissue types, the main eventual benefit of such projects will be the availability of the data for the research community to analyse further and use to inform future investigations (McLendon *et al.*, 2008; TCGA, 2017; Weinstein *et al.*, 2013). These serve as a vast resource of common and rare cancer types and are publicly available to analyse further (cBioPortal, 2017; TCGA, 2017; Zhang *et al.*, 2011). This also applies to the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) project which focuses on breast cancer which also aimed to identify novel molecular subtypes (Curtis *et al.*, 2012). They performed an analysis of 2433 breast cancer samples with long-term clinical data, gene expression, copy number variants, and 173 genes sequenced which identified 40 driver mutations in breast cancer in addition to further support for molecular subtyping to identify patient groups with different clinical outcomes (Pereira *et al.*, 2016).

## 1.1.6 Genomic Cancer Medicine

There is much anticipation in cancer research for genomics technologies to have a clinical impact in cancer medicine: from diagnosis and prognosis to treatment developments and strategies. These may result either from direct use of genome or RNA-Seq in clinical laboratories or indirectly from biomarkers and treatments developed with research facilitated by genomics. This second strategy is likely to have a more immediate patient benefit due to the cost of genome sequencing, particularly considering adoption



in public healthcare systems with a limited budget.

#### 1.1.6.1 Cancer Genes and Driver Mutations

There are two main categories of “cancer genes” (Futreal *et al.*, 2001). Oncogenes are those activated in cancers either by gain of function mutations in proto-oncogenes, amplification of DNA copies, or elevated gene expression. Their normal functions are typically to regulate stem cells or to promote cellular growth and recurrent mutations are typically concentrated to particular gene regions. Conversely, tumour suppressor genes are those inactivated in cancer either by loss of function mutations, deletion of DNA copies, repression of gene expression, or hypermethylation. Their normal functions are typically to regulate cell division, DNA repair, and cell signalling.

Detecting these cancer genes is a major challenge in cancer biology and has been revolutionised by genomic technologies. Recurrent mutations, or DNA copy number variants and differential gene expression or DNA methylation are all indicative of cancer genes (Mattison *et al.*, 2009), which can be detected in genomics data (Pereira *et al.*, 2016; Weinstein *et al.*, 2013). Important “driver” cancer genes (Stratton *et al.*, 2009) are difficult to detect from “passenger” mutations due to patient variation, tumour heterogeneity, and genomic instability. However, many cancer genes have been replicated from previous studies or well supported from genomics data. There remains the challenge of translating the identification of cancer genes to patient benefit with characterisation of variants of unknown significance, which mutation or gene expression markers can be used to monitor tumour progression or treatment response, and design of therapeutic intervention against many molecular target for which they have yet to be developed or repurposed from other disease to cancers.

Driver mutations can be identified by whether they co-occur or are mutually exclusive with mutations in other genes in cancers, are recurrently mutated across a significant proportion of samples for a specific tissue type, or if mutations are recurrent across different cancer tissue types (cBioPortal, 2017; Pereira *et al.*, 2016; COSMIC, 2016; Weinstein *et al.*, 2013; Zhang *et al.*, 2011). Approximately 140 driver mutations have been identified, including many novel genes in particular cancers from genomics studies, with 2–8 in typically occurring in each tumour usually affecting cell fate, survival, or genome maintenance (Vogelstein *et al.*, 2013).

#### **1.1.6.2 Personalised or Precision Cancer Medicine**

The notion of using a patient’s genome to tailor healthcare to an individual has been appealing since the advent of genomics, popularised with the term “personalised medicine”. This approach was expected to span from preventative lifestyle advice to effective treatments. Personalised medicine was intended contrast with current strategies of health advice, screening, prognostics, and treatments based on what works well with the majority of the population, highlighting that adverse effects of treatments occur in a significant subpopulation and that many clinical studies are dominated by Western populations of European ancestry and may not generalise to other populations.

While the importance of genomics is still recognised in translational cancer research, it’s potential has been emphasised particularly in molecular diagnosis, prognosis, and treatments of patients already presenting with cancers in the clinic rather than preventative medicine. This is in part due to the vast number of variants of unknown clinical significance, the ethical issue of reporting on incidental findings, and the regulatory issues direct-to-consumer genetics companies have encountered offering health risk assessment.

More recently the term “Genomic medicine” has been preferred to describe the paradigm of treating cancers by their genomic features, particularly grouping patients by the mutation, expression, or DNA methylation profiles of their cancers. Radical proponents advocate for these molecular subtypes to supersede tissue or cell type specific diagnosis of cancers. However, in practice they are often used in combination, with clinical and pathological factors being informative of prognosis and surgical training specialising by organ system. The related term of “precision medicine” also stems from this trend with the rationale to target these molecular subtypes with separate treatment strategies, particularly in developing and applying treatments targeted against a particular mutation specific to cancers. To this end much research in this field is focused on identifying mutations and gene expression signatures amenable to distinguishing cancers, particularly oncogenic driver mutations, and developing treatments against them.

##### **1.1.6.2.1 Molecular Diagnostics and Pan-Cancer Medicine**

There is growing support for the use of molecular tools such as mutations or gene expression signatures to diagnose tumour subtypes in replacement or addition to tissue of origin or histology. This is particularly important in breast cancer where analysis of

molecular data detected several distinct “intrinsic subtypes” with differences in malignancy and patient outcome which were distinguished by molecular mechanisms rather than tissue or cellular phenotype (Parker *et al.*, 2009; Perou *et al.*, 2000). Conversely, common molecular mechanisms may be shared between cancers across tissue types as discovered by the “Pan cancer” studies, such as those conducted by the TCGA and ICGC projects, which combined molecular profiles across tissue types Weinstein *et al.* (2013). The molecular subtypes could feasibly be included in clinic testing as a panel of biomarkers for diagnostics and prognosis. Such biomarkers also have the potential to monitor drug response or risk of recurrence. This also raises the need for development of treatments for targeting these molecular subtypes.

### **1.1.6.3 Targeted Therapeutics and Pharmacogenomics**

Targeted therapies with specificity against a molecular target are emerging as precision cancer medicine. Molecular targets can be tested in laboratory conditions with RNA interference or pharmacological agents. Identification of molecular targets is important for developing novel anti-cancer treatments along with validation and drug testing. For oncogenic mutations, the recurrent mutant variant or overexpressed gene is directly inhibited using structure-aided drug design or compound screening. However, oncogenes with high homology to other genes or tumour suppressor genes (where lost in cancers) are not amenable to direct targeting (Kaelin, Jr, 2009).

Despite controversy over their prohibitively high cost (PHARMAC, 2016), targeted therapeutics have been applied as monoclonal antibodies against oncogenes (such as *HER2*) with relative success in clinical trials (Miles, 2001), generating considerable interest in wider application of this approach. Targeted therapeutics have potential to have applications across cancer tissue types, specificity against tumour cells, wide therapeutic windows, and combination therapies (even in advanced disease or as a chemopreventative in high-risk individuals).

#### **1.1.6.3.1 Targeting Oncogenic Driver Mutations**

Oncogene targeted therapies have also been developed with some examples of effective clinical application against cancers. However, they already begun to manifest problems with resistance, recurrence, tissue specificity, and design of inhibitors specific to oncogenic variants rather than proto-oncogene precursors. Targeted anticancer therapeutics can exploit complex interactions to distinguish normal and cancerous cells which may benefit from studies of gene regulation or interaction networks. The unexpected syn-

ergy between inhibitors of the oncogenes  $BRAF^{V600E}$  and  $EGFR$  in colorectal cancer is an example of such a system Prahallad *et al.* (2012).

Despite successful application of vemurafenib against  $BRAF^{V600E}$  in melanomas Dienstmann and Tabernero (2011); Ravnán and Matalka (2012), colorectal cancers with  $BRAF^{V600E}$  mutations have poor prognosis and lack drug response. Prahallad *et al.* (2012) used an RNAi screen and found that  $EGFR$  inhibition is synergistic with vemurafenib against  $BRAF^{V600E}$  in colon cell lines and xenografts due feedback activation of  $EGFR$ . Vemurafenib which induced rapid reactivation of MAPK/ERK signalling via  $EGFR$  in colorectal cell lines in a tissue-specific manner Corcoran *et al.* (2012), although these may be relevant to acquired resistance in melanoma Sun *et al.* (2014). Thus combination therapies against several molecular pathways may be necessary to anticipate acquired resistance Ravnán and Matalka (2012) and targeted therapeutics may be further refined from understanding the pathway structure and functional interactions cancer cells.

#### 1.1.6.4 Systems and Network Biology

It is also important to consider that driver mutations in oncogenes and tumour suppressor genes do not occur in isolation. The genetic interaction, regulatory and cellular signaling, and metabolic reactions of are all inter-related and may each be perturbed by aberrations in gene function occurring in cancers. These relationships can be represented by biological networks, mapping pairs of genes with a particular relationship. Due to the complexity of a cell, these molecular networks are very large consisting of thousands of nodes such as genes or proteins.

The properties of large networks were first studied by constructing random networks by randomly linking a fixed number of nodes (Erdős and Rényi, 1959, 1960). Despite the random nature of these networks, properties such as their connectivity were well characterised. The vertex degree (number of partners for each node) of random network follows a Poisson distribution, however this property does not hold in nature, suggesting that natural networks are non-random or not formed in this way Barabási and Oltvai (2004).

This work formed the foundation for studying complex networks (van Steen, 2010), which model features of real world networks not found in Erdős and Rényi's random networks (Erdős and Rényi, 1959, 1960). The small world property, made popular by findings in social networks (Travers and Milgram, 1969), is the remarkably short path lengths between any nodes in a small world network. A small world network is

well-connected with a characteristic path length (the average length of shortest paths between all pairs of nodes) proportional to the logarithm of the number of nodes. Watts and Strogatz (1998) developed a model of random rewiring of a regular network to construct random networks with the small world property and a high clustering coefficient. While these properties are more representative of networks occurring in nature, their model is limited by the degree distribution which converges to a Poisson distribution as it is rewired Barrat and Weigt (2000).

The vertex degree distribution of naturally occurring networks often follows a power law distribution with the majority of nodes having far fewer connections than average and a small subset of highly connected network ‘hubs’ Barabási and Albert (1999). Hubs further differentiate into ‘party’ hubs (which interact simultaneously with many partners) and ‘date’ hubs (which interact with different partners in different conditions) Han *et al.* (2004). Network hubs can also be classed as associative or dissociative depending on whether they tend toward or away from connecting directly to other network hubs (van Steen, 2010). The associative and dissociative properties can also be used to test whether nodes of a particular subgroup (e.g., gene function) associate with each other.

Barabási and Albert (1999) constructed a network model in an entirely different way to randomly generate scale-free networks which have a power law degree distribution. They constructed random networks by preferential attachment, modelling growth of a network by sequentially adding nodes with links to existing nodes. The scale-free nature of the random networks was ensured by adding new nodes with an increasing probability of attachment to an existing node if it has higher degree. These networks successfully capture the scale-free nature of many real world networks with short characteristic path length and low eccentricity resulting in super small worlds Barabási and Albert (1999). Scale-free networks are limited by a low clustering coefficient and lack of modular structure; however, they have enabled the study of scale-free network topology and served as a basis for modified scale-free models (Dorogovtsev and Mendes, 2003; Holme and Kim, 2002).

Han *et al.* (2004) observed dynamic modularity in biological networks and suggested the network structure may underpin genetic robustness and plasticity. They focus on network hubs which are more likely to be essential genes and define the subgroups of hubs based on correlation of gene expression with protein-protein interaction partners: ‘party’ hubs (which interact simultaneously with many partners) and ‘date’ hubs (which interact with different partners in different conditions). Party and date hubs occurred

most frequently within and between network modules respectively. Party hubs were considered local regulators, whereas date hubs were considered important to network connectivity as global regulators. This distinction between classes of network hubs was supported by differences in tissue specificity and clinical relevance as a proposed predictor of clinical outcome in breast cancer with an AUROC of 0.784 Taylor *et al.* (2009). However, correlation between expression and protein interactions were not robustly reproduced. The importance of date hubs has been criticised for assuming a bimodal distribution and basing the global importance of data hubs on a small subset Agarwal *et al.* (2010). As an alternative interpretation, (Agarwal *et al.*, 2010) suggest the importance of interactions rather than network hubs as interactions important to the network were between functionally similar proteins. Network hubs can also be classed as associative or dissociative depending on whether they tend toward or away from connecting directly to other network hubs (van Steen 2010). The associative and dissociative properties can also be used to test whether nodes of a particular subgroup (e.g., gene function) associate with each other.

Applications of network theory are diverse, including uses in social sciences, engineering, and computer science. Due to their complexity and difficulty of gathering sufficient empirical data, biological applications of network theory are relatively unexplored. High-throughput technologies such as siRNA screens, two-hybrid screens, microarrays and massively parallel sequencing have made generating genome-scale molecular data feasible and enabled analysis of biological networks at the molecular level. Many types of inter-related molecular networks can be constructed and analysed, depending on the biological application. Genetic interaction networks will be the focus of this project because they are relatively unexplored compared to other molecular networks, have potential for applications in drug discovery (particularly cancer treatment), and may lead to better understanding of the role of genetics in cellular function and disease. Genetic interactions are usually studied at a high-throughput scale in simple model organisms such as bacteria, yeasts or the nematode worm; studies in humans, mammals, and non-model organisms (where applications would have the most societal impact) are limited by cost, time and labour constraints. Computational approaches with effective predictive models are the only feasible approach to study the connectivity of a biological network in a complex metazoan cell at the genome-scale.

#### 1.1.6.4.1 Network Medicine, and Polypharmacology

Molecular networks are biological networks consisting on biological molecules including genes, transcripts (with non-coding and microRNAs), or proteins related by known interactions and gene regulatory or metabolic pathways. Targeted therapeutics have had some success for drug discovery, particularly in anticancer applications, including exploiting these molecular networks by designing combination therapies and applying a network pharmacology framework Hopkins (2008). Rational design of drugs selective to a single target has often failed to deliver clinical efficacy. Many existing effective drugs modulate multiple proteins, having been selected for biological effects or clinical outcome rather than molecular targets. Proponents of network biology and polypharmacology (specific binding to multiple targets) recommend to develop drugs with a desired target profile designed for the target topology Barabási and Oltvai (2004); Hopkins (2008). Multi-target treatments aim to achieve a clinical outcome through modulation of molecular networks since the genetic robustness of a cell often compensates for loss of a single molecular target.

While multi-target drugs may be more difficult to design, they are faster to test clinically than drug combinations which are usually required to be tested separately first Hopkins (2008). Synthetic lethal treatments for cancer, drug combinations and multi-target drugs to combat resistance to chemotherapy and antibiotics can be informed by biological networks Barabási and Oltvai (2004); Hopkins (2008). Further optimisation of timing and dosing of drug combinations may increase efficacy and needs to be explored for combination effects with low efficacy as separate treatments. Low doses and drug holidays are other counter intuitive approaches which may increase clinical efficacy, reduce adverse effects, and reduce drug resistance (Sun *et al.*, 2014; Tsai *et al.*, 2012).

A molecular map of the interactions and pathways in the mammalian cellular network has the potential to impact upon drug design and clinical practice, particularly in treatment of cancer and infectious disease. Characterisation of the target system and impact of existing treatments, such as *BRAF*<sup>V600E</sup> and *EGFR* inhibitors, enable wider application of the mechanisms for such interventions exploiting genetic interactions or pathways. This could lead to development of more effective treatment interventions for these systems and prediction of similar molecular systems for development of novel drug targets and combinations.

## 1.2 A Synthetic Lethal Approach to Cancer Medicine

Synthetic lethality has vast potential to improve cancer medicine by expanding application of targeted therapeutics to include inactivation of tumour suppressors and genes that are difficult to target directly. Synthetic lethal interactions are also studied for gene function and drug mode-of-action in model organisms. This section introduces the concept of synthetic lethality as it was originally conceived and how it has been adopted conceptually in cancer research. Detecting these interactions at scale and interpreting them is the focus of this thesis, hence we start with an overview of the concepts involved, initial work on the interaction, and the rationale for applications to cancer. Specific investigations into synthetic lethality in cancer, detection by experimental screening, and prediction by computational analysis will then be reviewed.


### 1.2.1 Synthetic Lethal Genetic Interactions

Genetic interactions are a core concept of molecular biology, discovered among earliest investigations of Mendelian genetics, and receiving revived interest with new technologies and potential applications. Biological epistasis is the effect of an allele at one locus “masking” the phenotype of another locus (Bateson and Mendel, 1909). Statistical epistasis is where there is significant disparity between the observed and expected phenotype of a double mutant, compared to the respective phenotypes of single mutants and the wild-type (Fisher, 1919). Fisher’s definition lends itself to quantitative traits and more broadly encompasses synthetic genetic interactions (SGIs). These have become popular for studies in yeast genetics and cancer drug design (Boone *et al.*, 2007; Kaelin, Jr, 2005).

Synthetic genetic interactions are substantial deviations of growth or viability from the expected null mutant phenotype (of an organism or cell) assuming additive (deleterious) effects of the single mutants. The double mutant does not necessarily have either single mutant phenotype (as shown for cellular growth phenotypes in Figure 1.1). Most SGIs are more viable than either single mutant or less viable than the expected double mutant. Mutations are “synergistic” in negative SGIs with more deviation from the wild-type than expected. Formally, “synthetic sick” (SSL) and “synthetic lethal” (SL) interactions are negative SGIs giving growth inhibition and inviability respectively. Synthetic lethality in cancer research more broadly describes any negative SGI with specific inhibition of a mutant cell, including SSL interactions. Mutations are “alleviating” in positive SGIs with less deviation from the wild-type than expected. For



viability, “suppression” and “rescue” are positive SGIs giving at least partial restoration of wild-type growth from single mutants with growth impairment and lethal phenotypes respectively. Negative SGIs were markedly more common than positive SGIs in a number of studies in model systems Boucher and Jenna (2013); Tong *et al.* (2004).



### 1.2.2 Synthetic Lethal Concepts in Genetics

Synthetic lethal genes are generally regarded to arise due to functional redundancy. Due to the functional level of SGIs, synthetic lethal genes do not need directly interact, nor be expressed in the same cell or at the same developmental stage: serving related functions is sufficient to affect cell (or organism) viability and be relevant to drug-mode-of-action cancer biology. Combined loss of genes performing an essential or important function in a cell are therefore deleterious. Synthetic lethal gene pairs are therefore pairwise essential with “induced essentiality”: each synthetic lethal gene becomes essential to the cell upon loss of the other.

Since synthetic lethal gene partners can be affected by extracellular stimuli and chemical, essentiality of synthetic lethal genes can be induced by the environment of a cell. An environmental stress conditions may inhibit one or the other synthetic lethal gene, such as exposure to chemicals, in which case the synthetic lethal partner gene is “conditionally essential” (Hillenmeyer, 2008). Thus the evolutionary rationale for the abundance of SGIs (compared to the surprisingly low number of essential genes) in a

Eukaryotic genome attributed to genetic functional redundancy and network robustness of a cell which are advantageous to survival.

Biological functions are typically performed by a pathway of genes (or their products), may genes of the same pathway may be interchangeable as synthetic lethal partners of a particular gene since loss of the pathway is deleterious without the synthetic lethal partner gene. Therefore biological pathways can be subject to induced essentiality under loss of a gene and synthetic lethality be defined occur at pathway level or occur in a gene regulation network.

### 1.2.3 Studies of Synthetic Lethality

Genetic high-throughput screens have identified unexpected, functionally informative, and clinically relevant synthetic lethal interactions; including synthetic lethal partners of genes recurrently mutated in cancer or attributed to familial early-onset cancers. While screening presents an appealing strategy for synthetic lethal discovery, computational approaches are becoming popular as an alternative or complement to experimental methods to overcome inherent bias and limitations of experimental screens. An array of recently developed computational methods (Jerby-Arnon *et al.*, 2014; Lu *et al.*, 2015; Tiong *et al.*, 2014; Wang and Simon, 2013; Wappett, 2014) show the need for synthetic lethal discovery in the fundamental genetics and translational cancer research community. However, existing computational methods are not suitable for queries of genomic data for interacting partners of a particular gene: they have been applied pairwise across the genome, do not have software released to apply the methodology, or lack statistical measures of error for further analysis. A robust prediction of gene interactions is an effective and practical approach at a scale of the entire genome for ideal translational applications, analysis of biological systems, and constructing functional gene networks.

#### 1.2.3.1 Synthetic Lethal Pathways and Networks

SGIs are very common in genomes, with a  $4\times$  more interactions detected with synthetic gene array mating screens than protein-protein interactions yeast-2-hybrid studies (Tong *et al.*, 2004). The SGI network is scale-free with power-law vertex degree distribution and low average shortest path length (3.3) as expected for a complex biological network (Barabási and Oltvai, 2004). Highly connected “hub” genes with the highest number of links (vertex degree) are functionally important with many negative

SGI hubs involved in cell cycle regulation and many positive SGI hubs involved in translation (Baryshnikova *et al.*, 2010b; Costanzo *et al.*, 2010). Negative SGIs were far more common than positive SGIs, with synthetic gene loss being more likely to be deleterious to cell than advantageous which indicates that synthetic lethality may be comparably easier to detect than other SGIs.

Essential pathways are highly buffered with  $5\times$  more interactions than other SGIs, consistent with strong selection for survival, as found with conditional and partial mutations in essential genes (Davierwala *et al.*, 2005). This SGI network had scale-free topology and rarely shared interactions with the protein-protein interaction network. These networks are related by an “orthogonal” relationship: shared partners in one network tend to be themselves connected directly in the other network. Essential genes were likely to have closely related functions, whereas non-essential networks more relatively more inclined to have SGIs between distinct biological pathways.

### 1.2.3.1.1 Conservation and Evolution of Synthetic Lethality

There is poor conservation of specific SGIs between *S. cerevisiae* and *S. pombe* with 29% of the interactions tested in both distantly related species being conserved between them (Dixon2008). The remaining interactions show high species-specific differences; however, many of the species specific interactions were still conserved between biological pathways, protein complexes, or protein-protein interaction modules. Similarly, conservation of pathway redundancy was also found between Eukaryotes (*S. cerevisiae*) and prokaryotes (*E. coli*) (Butland *et al.*, 2008). Negative SGIs were more likely to be conserved between biological pathways, whereas positive SGIs were more likely to be conserved within a pathway or protein complex (Roguev *et al.*, 2008).

A modest 5% of interactions were conserved between unicellular (*S. cerevisiae*) and multicellular (*C. elegans*) organisms but the nematode SGI network had similar scale-free topology and modularity despite difficulties metazoan RNAi screens being incomplete knockouts compared to null mutations in yeast (Bussey *et al.*, 2006). The nematode SGI screen identified network hubs with important interactions to orthologues of known human disease genes (Lehner *et al.*, 2006). Despite the lack of direct conservation of SGIs between yeasts and nematode worms, genetic redundancy at the gene or pathway level may yet be consistent with an induced essentiality model of SGIs where gene functions are conserved with network restructuring over evolutionary change (Tischler *et al.*, 2008). While nematode models are more closely related to human cells, cancer cells can present growth and viability phenotypes more comparable

to yeast models. Therefore findings from both SGA and RNAi models are relevant to understanding cellular network structure and in healthy and cancerous human cells. RNAi has also been applied to human and mouse cancer cells in cell culture and genetic screening experiments. These findings suggest that SGI network “rewiring” is a concern for identifying specific synthetic lethal interactions in cancer and a pathway approach may be more robust in the context of evolution, patient variation, tumour heterogeneity, and disease progression.

### 1.2.4 Synthetic Lethal Concepts in Cancer

Loss of function occurs in many genes in cancers including tumour suppressors and yet few interventions target such mutations compared to targeted therapies for gain of function mutation in oncogenes (Kaelin, Jr, 2005). Synthetic lethality is a powerful design strategy for therapies selective against loss of gene function with potential for application against a range of genes and diseases (Fece de la Cruz *et al.*, 2015; Kaelin, Jr, 2009). Since synthetic lethality affects cellular viability by indirect functional relationships genes, it is suitable for indirectly targeting of mutations in cancers. Once synthetic lethal partners of cancer genes are identified, targeted therapeutics can be applied against them. When genes are disrupted in cancers, the induced essentiality of synthetic lethal partners is a vulnerability that may be exploited for anti-cancer therapy. This has the potential to be very specific against cancer cells (with the target mutation) over non-cancer cells (with a functional compensating gene). Analogous to “oncogene addiction”, where cancer cells adapt to particular oncogenic growth signals and become reliant on them to remain viable (Luo *et al.*, 2009; Weinstein, 2000), synthetic lethal partners of inactivated tumour suppressors are required to maintain cancer cell viability and proliferation as such they are subject to “non-oncogene addiction” and are feasible anti-cancer drug targets.

The synthetic lethal approach to cancer medicine is most amenable to loss of function mutations in tumour suppressor genes, where it would feasibly be effective against any loss of function mutation across the tumour suppressor with a viable synthetic lethal partner gene (as shown in Figure 1.2). However, the approach may also be suitable for cases where cancer cells have mutations where the normal function of the gene is disrupted such as if it were overexpression (“synthetic dosage lethality”) or if an oncogene interfered with the function of the proto-oncogenic variant such as competitive inhibition. Thus synthetic lethality expands the range of cancer-specific mutations feasible to target with targeted therapeutics to absence of tumour suppressor genes and




Figure 1.2: **Synthetic lethality in cancer.** Rationale of exploiting synthetic lethality for specificity against a tumour suppressor gene (e.g., *CDH1*) while other cells are spared under the inhibition of a partner gene.

distinguishing highly homologous oncogenes by functional differences by targeting their synthetic lethal partners.

### 1.2.5 Clinical Impact of Synthetic Lethality in Cancer

The synthetic lethal interaction of *BRCA1* or *BRCA2* with *PARP1* in breast cancer is an example of how gene interactions are important in cancer, including translation to the clinic. These genetic interactions enable specific targeting of mutations in *BRCA1* or *BRCA2* tumour suppressor genes with PARP inhibitors by inducing synthetic lethality in breast cancer (Farmer *et al.*, 2005). PARP inhibitors are one of the first targeted therapeutics against a tumour suppressor mutation with success in clinical trials.

*BRCA1* or *BRCA2* and *PARP1* genes demonstrate the application of the synthetic lethal approach to cancer therapy Ashworth (2008); Kaelin, Jr (2005). *BRCA1* and *BRCA2* are homologous DNA repair genes, widely known as tumour suppressors; mutation carriers have substantially increased risk of breast (risk by age 70 of 57% for *BRCA1* and 59% for *BRCA2*) and ovarian cancers (risk by age 70 of 40% for *BRCA1* and 18% for *BRCA2*) (Chen and Parmigiani, 2007). The *BRCA1* or *BRCA2* genes, which usually repair DNA or destroy the cell if it cannot be repaired, have inactivating

somatic mutations in some familial and sporadic cancers. Poly-ADP-ribose polymerase (PARP) genes are tumour suppressor genes involved in base excision DNA repair. Loss of PARP activity results in single-stranded DNA breaks. However, *PARP1*<sup>-/-</sup> knock-out mice are viable and healthy indicating low toxicity from PARP inhibition (Bryant *et al.*, 2005).

Bryant *et al.* (2005) showed that *BRCA2*<sup>-/-</sup> cells were sensitive to PARP inhibition by siRNA of *PARP1* or drug inhibition (which targets *PARP1* and *PARP2*) using Chinese hamster ovary cells, MCF7 and MDA-MB-231 breast cell lines. This effect was sufficient to kill mouse tumour xenografts and showed high specificity to *BRCA2* deficient cells in culture and xenografts. Farmer *et al.* (2005) replicated these results in embryonic stem cells and showed that *BRCA1*<sup>-/-</sup> cells were also sensitive to PARP inhibition relative to the wild-type with siRNA and drug experiments in cell culture and drug activity against *BRCA1* or *BRCA2* deficient embryonic stem cell mouse xenografts. They found evidence that PARP inhibition causes DNA lesions, usually repaired in wild-type cells, which lead to chromosomal instability, cell cycle arrest, and induction of apoptosis in *BRCA1* or *BRCA2* deficient cells. Therefore, the pathways cooperate to repair DNA giving a plausible mechanism for combined loss as an effective anti-cancer treatment.

Thus PARP inhibitors have potential for clinical use against *BRCA1* or *BRCA2* mutations in hereditary and sporadic cancers (Ashworth 2008; Kaelin2005). PARP inhibition has been found to be effective in cancer patients carrying *BRCA1* or *BRCA2* mutations and some other ovarian cancers, suggesting synthetic lethality between PARP and other DNA repair pathways (Ström and Helleday, 2012). This supports the potential for PARP inhibition as a chemo-preventative alternative to prophylactic surgery for high risk individuals with *BRCA1* or *BRCA2* mutations (Ström and Helleday, 2012). Hormone-based therapy has also been suggested as a chemo-preventative in such high risk individuals and aromatase inhibitors have completed phase I clinical trials for this purpose (Bozovic-Spasojevic2012). Ström and Helleday (2012) also postulate increased efficacy of PARP inhibitors in the hypoxic DNA-damaging tumour micro-environment.

A PARP inhibitor, olaparib, showed fewer adverse effects than cytotoxic chemotherapy and anti-tumour activity in phase I trials against *BRCA1* or *BRCA2* deficient familial breast, ovarian, and prostate cancers (Fong *et al.*, 2009) and sporadic ovarian cancer (Fong *et al.*, 2010). AstraZeneca has reported phase II trials showing the treatment is effective in *BRCA1* or *BRCA2* deficient breast (Tutt *et al.*, 2010) and ovarian cancers (Audeh *et al.*, 2010) with a favourable therapeutic window and similar

toxicity between carriers of *BRCA1* or *BRCA2* mutations and sporadic cases. AstraZeneca announced that olaparib has begun phase III trials for breast and ovarian cancers in 2013. Mixed results in phase II trials in ovarian cancer are behind the delays addressed by retrospective analysis of the cohort subgroup with confirmed mutation of *BRCA1* or *BRCA2* genes in the tumour; unsurprisingly these patients, benefit most from the PARP inhibitor treatment and have increased platinum sensitivity in combination treatment. This demonstrates the clinical impact of a well characterised system of synthetic lethality with known cancer risk genes. Synthetic lethality has the benefit of being effective against inactivation of tumour suppressor genes by any means, broader than targeting a particular oncogenic mutation (Kaelin, Jr, 2005). The targeted therapy is effective in both sporadic and hereditary *BRCA1* or *BRCA2* deficient tumours acting against an oncogenic molecular aberration across several tissues.

[Update re. FDA approval for Ovarian]

These PARP inhibitors are FDA approved for some cancers McLachlan *et al.* (2016), are effective against germline and sporadic *BRCA1* or *BRCA2* mutations, and are a potential prevention alternative to prophylactic surgery for high risk mutation carriers Ström and Helleday (2012).

### 1.2.6 High-throughput Screening for Synthetic Lethality

The function of signalling pathways and combinations of interacting genes are important in cancer research but classical genetics approaches have been limited to non-redundant pathways (Fraser, 2004). The emerging RNAi technologies have vastly expanded the potential for studying genetic redundancy in mammalian experimental models including testing experimentally for synthetic lethality (Fraser, 2004). Identifying synthetic lethality is crucial to study gene function, drug mechanisms, and design novel therapies (Lum *et al.*, 2004). Candidate selection of synthetic lethal gene pairs relevant to cancer has shown some success but is limited because interactions are difficult to predict; they can occur between seemingly unrelated pathways in model organisms (Costanzo *et al.*, 2011). While biologically informed hypotheses have had some success in synthetic lethal discovery (Bitler *et al.*, 2015; Bryant *et al.*, 2005; Farmer *et al.*, 2005), interactions occurring indirectly between distinct pathways would be missed (Boone *et al.*, 2007; Costanzo *et al.*, 2011). Scanning the entire genome for interactions against a clinically relevant gene is an emerging strategy being explored with high-throughput screens (Fece de la Cruz *et al.*, 2015) and computational approaches (Boucher and Jenna, 2013; van Steen, 2012).

Experimental screening for synthetic lethality is an appealing strategy for wider discovery of functional interactions *in vivo* despite many potential sources of error which must be considered. The synthetic lethal concept has both genetic and pharmacological screening applications to cancer research. Genetic screens, with RNAi to discover the specific genes involved, inform development of targeted therapies with a known mode of action, anticipated mechanisms of resistance, and biomarkers for treatment response. RNAi is a transient knockdown of gene expression more similar to the effect of drugs than complete gene loss and makes comparison to screens in model organisms difficult (Bussey *et al.*, 2006). The RNAi gene knockdown process has inherent toxicity to some cells, potential off-target effects, and issues with a high false positive rate. Therefore, it is important to validate any candidates in a secondary screen and replicate knockdown experiments with a number of independent shRNAs. Alternative gene knockout procedures have also been proposed for synthetic lethal screening including a genome-wide application of the CRIPR/Cas9/sgRNA genome editing technology (Sander and Joung, 2014), episomal gene transfer (Vargas *et al.*, 2004), or RNAi with lentiviral transfection for delivery of shRNA (Telford *et al.*, 2015). Genetic screens have potential for quantitative gene disruption experiments to selectively target overexpressed genes in cancer via synthetic dosage lethality. While powerful for understanding fundamental cellular function, analysis of isogenic cell lines is inherently limited by assuming only a single mutation differs between them despite susceptibility to “genetic drift” and cannot account for diverse genetic backgrounds or tumour heterogeneity (Fece de la Cruz *et al.*, 2015). Genetic screens thus identify targets to develop or repurpose targeted therapies for disease but alone will not directly identify a lead compound to develop for the market or clinical translation.

Chemical screens are immediately applicable to the clinic by directly screening for selective lead compounds with suitable pharmacological properties. However chemical screens lack a known mode of action, may affect many targets, and screen a narrow range of genes with existing drugs. With either approach there are many challenges translating candidates into the clinic such as finding targets relevant to a range of patients, validation of targets, accounting for a range of genetic (and epigenetic) contexts or tumour micro-environment, identifying effective synergistic combinations, enhancers of existing radiation or cytotoxic treatments, avoiding inherent or acquired drug resistance, and developing biomarkers for patients which will respond to synthetic lethal treatment, including integrating these into clinical trials and clinical practice. Identifying specific target genes is an effective way to anticipate such challenges, which



can be approached with genetic screens, so we will focus on these and computational alternatives. Screening methods have proven a fruitful area of research, despite being costly, laborious, and having many different sources of error. These limitations suggest a need for complementary computational approaches to synthetic lethal discovery.

### 1.2.6.1 Examples of Synthetic Lethal Screens

Overexpression of genes is another suitable application for synthetic lethality since overexpressed genes cannot be distinguished from the wild-type by direct sequence specific targeted therapy. Overexpression of oncogenes, such as *EGFR*, *MYC*, and *PIM1*, has been found to drive many cancers. *PIM1* is a candidate for synthetic lethal drug design in lymphomas and prostate cancers, where it interacts with *MYC* to drive cancer growth. van der Meer *et al.* (2014) performed an RNAi screen to for synthetic lethality between *PIM1* overexpression and gene knockdown in RWPE prostate cancer cell lines. *PLK1* gene knockdown and drug inhibition was an effective as a specific inhibitor of *PIM1* overexpressing prostate cells in cell culture and mouse tumour xenografts. *PLK1* inhibition reduced *MYC* expression in pre-clinical models, consistent with expression in human tumours which *PIM1* and *PLK1* are co-expressed and correlated with tumour grade. Thus RNAi screening was valuable to identify a therapeutic targets and biomarkers for patient response as demonstrated with the finding of *PLK1* as a candidate drug target against prostate cancer progression.

Hereditary leiomyomatosis and renal cell carcinoma (HLRCC) is a cancer syndrome of predisposition to benign tumours in the uterus and risk of malignant cancer of the kidney attributed to inherited mutations in fumarate hydratase (*FH*). Boettcher *et al.* (2014) performed an RNAi screen on HEK293T renal cells for synthetic lethality with *FH*. They found enrichment of haem metabolism (consistent with the literature) and adenylate cyclase pathways (consistent with cAMP dysregulation in *FH* mutant cells). Synthetic lethality between *FH* mutation and adenylate cyclases was validated with gene knockdown, drug experiments, and replicated across both HEK293T renal cells and VOK262 cells derived from a HLRCC patient, suggesting new potential treatments against the disease.

Similarly, hereditary diffuse gastric cancer (HDGC) is a cancer syndrome of predisposition to early-onset malignant stomach and breast cancers attributed to mutations in E-cadherin (*CDH1*). Telford *et al.* (2015) performed an RNAi screen on MCF10A breast cells for synthetic lethality with *CDH1*. They found enrichment of G-protein coupled receptors (GPCRs) and cytoskeletal gene functions. The results were consis-

tent with a concurrent drug compound screen with a number of candidates validated by lentiviral shRNA gene knockdown and drug testing including inhibitors of Janus kinase, histone deacetylases, phosphoinositide 3-kinase, aurora kinase, and tyrosine kinases. Therefore the synthetic lethal strategy has potential for clinical impact against HDGC, with particular interest in interventions with low adverse effects for chemoprevention, including repurposing existing approved drugs for activity against *CDH1* deficient cancers.

RNAi screening for synthetic lethality is also useful for functional genetics to understand drug sensitivity. Aarts *et al.* (2015) screened WiDr colorectal cells for synthetic lethality between *WEE1* inhibitor treatment and an RNAi library of 1206 genes with functions known to be amenable to drug treatment or important in cancer such as kinases, phosphatases, tumour suppressors, and DNA repair (a pathway *WEE1* regulates). Screening identified a number of synthetic lethal candidates including genes involved in cell cycle regulation, DNA replication, repair, homologous recombination, and Fanconi anaemia. Synthetic lethality with cell-cycle and DNA repair genes was consistent with the literature and validation in a panel of breast and colorectal cell lines supported checkpoint kinases, Fanconi anaemia, and homologous recombination as synthetic lethal partners of *WEE1*. These results show that synthetic lethality can be used to improve drug sensitivity as a combination treatment, especially to exploit genomic instability and DNA repair, which are known to be clinically applicable from previous results with *BRCA1* or *BRCA2* genes and PARP inhibitors (Lord *et al.*, 2015). Therefore, *WEE1* inhibitors are an example of treatment which could be repurposed with the synthetic lethal strategy and similar findings would be valuable to clinicians as a source of biomarkers and novel treatments. While using a panel of cell lines to replicate findings across genetic background is a promising approach to ensure wide clinical application of validated synthetic lethal partners, a computational approach may be more effective as it could account for wider patient variation than scaling up intensive experiments on a wide array of cell lines and could screen beyond limited candidates from an RNAi library.

Chemical genetic screens are also a viable strategy to identify therapeutically relevant synthetic lethal interactions. Bitler *et al.* (2015) investigated *ARID1A* mutations, aberrations in chromatin remodelling known to be common in ovarian cancers, for drug response. Ovarian RMG1 cells were screened for drug response specific to *ARID1A* knockdown cells. They used *ARID1A* gene knockdown for consistent genetic background, with control experiments and 3D cell culture to ensure relevance to drug

activity in the tumour micro-environment. Screening a panel of commercially available drugs targeting epigenetic regulators found *ESH2* methyltransferase inhibitors effective and specific against *ARID1A* mutation with validation in a panel of ovarian cell lines. Synthetic lethality between *ARID1A* and *ESH2* was supported by decreases in H3K27Me3 epigenetic marks and markers of apoptosis in response to *ESH2* inhibitors. This was mechanistically supported with differential expression of *PIK3IP1* and association of both synthetic lethal genes with the *PIK3IP1* promoter identifying the PI3K-AKT signalling pathway as disrupted when both genes are inhibited. This successfully demonstrates the importance of synthetic lethality in epigenetic regulators, identifies a therapeutically relevant synthetic lethal interaction, and shows that chemical genetic screens could model drug response and combination therapy in cancer cells. However this approach is limited to finding synthetic lethal interactions between genes with known similar function, which may not be the most suitable for treatment. Further limiting experiments to genes with existing targeted drugs reduces the number of synthetic lethal interactions detected, assumes on their drug specificity to a particular target, and many of these drugs are not clinically available yet anyway as they are still in clinical trials for other diseases or are not supported by healthcare systems in many countries.

The examples above show that high-throughput screens are an effective approach to discover synthetic lethality in cancer with a wide range of applications. Screens are more comprehensive than hypothesis-driven candidate gene approaches and successfully find known and novel synthetic lethal interactions with potential for rapid clinical application. They have the power to test mode of action of drugs, find unexpected synthetic lethal interactions between pathways, or identify effective treatment strategies without needing a clear mechanism. However, synthetic lethal screens are costly, labour-intensive, error-prone, and biased towards genes with effective RNAi knockdown libraries. Limited genetic background, lethality to wild-type cell during gene knockdown, off-target effects, and difficulty replicating synthetic lethality across different cell lines, tissues, laboratories, or conditions stems from a high false positive rate and a lack of standardised thresholds to identify synthetic lethality in a high-throughput screen. Therefore there is a need for replication, validation, and alternative approaches to identify synthetic lethal candidates. Varied conditions between experimental screens and differences between RNAi or drug screens makes meta-analysis difficult. Thus genome-scale synthetic lethal experiments are not feasible, even in model organisms, so a computational approach would be more suitable for this task.

## 1.2.7 Computational Prediction of Synthetic Lethality

### 1.2.7.1 Bioinformatics approaches to gene interactions

Prediction of gene interaction networks is a feasible alternative to high-throughput screening with biological importance and clinical relevance. There are many existing methods to predict gene networks, as reviewed by van Steen (2012) and Boucher and Jenna (2013) and summarised in Table 1.1. However, many of these methods have limitations including the requirement for existing SGI data, several data inputs, and reliability of gene function annotation. Many of the existing methods also assume conservation of individual interactions between species, which has been found not to hold in yeast studies (Dixon *et al.*, 2008). Tissue specificity is important in gene regulation and gene expression, which are used as predictors of genetic interaction. However, tissue specific of genetic interactions cannot be explored in yeast studies and has not been considered in many studies of multicellular model organisms, human networks, or cancers. Similarly, investigation into tissue specific of protein-protein interactions (PPIs), an important predictor of genetic interactions, is difficult given the high-throughput two-hybrid screens occur out of cellular context for multicellular organisms.

Table 1.1: Methods for Predicting Genetic Interactions

Method	Input Data	Species	Source	Tool Offered
Between Pathways Model	PPI, SGI	<i>S. cerevisiae</i>	Kelley and Ideker (2005)	
Within Pathways Model	PPI, SGI	<i>S. cerevisiae</i>	Kelley and Ideker (2005)	
Decision Tree	PPI, expression, phenotype	<i>S. cerevisiae</i>	Wong <i>et al.</i> (2004)	2 Hop
Logistic Regression	SGI, PPI, co-expression, phenotype	<i>C. elegans</i>	Zhong and Sternberg (2006)	Gene Orienteer
Network Sampling	SGI, PPI, GO	<i>S. cerevisiae</i>	Le Meur and Gentleman (2008) Le Meur <i>et al.</i> (2014)	SLGI(R)
Random Walk	GO, PPI, expression	<i>S. cerevisiae</i> <i>C. elegans</i>	Chipman and Singh (2009)	
Shared Function	Co-expression, PPI, text mining, phylogeny	<i>C. elegans</i>	Lee <i>et al.</i> (2010b)	WormNet
Logistic Regression	Co-expression, PPI, phenotype	<i>C. elegans</i>	Lee <i>et al.</i> (2010a)	GI Finder
Jaccard Index	GO, SGI, PPI, phenotype	Eukarya	Hoehndorf <i>et al.</i> (2013)	
Machine Learning			Pandey <i>et al.</i> (2010)	MNMC
Machine Learning Meta-Analysis			Wu <i>et al.</i> (2014)	MetaSL
Flux Variability Analysis	Metabolism	<i>E. coli</i>	Güell <i>et al.</i> (2014)	
Flux Balance Analysis		<i>Mycoplasma pneumoniae</i>		
Network Simulation				

There are a number of existing computational methods for predicting synthetic lethal gene pairs in humans with a specific interest in cancer (as summarised in 1.2). While these demonstrate the power and need for predictions of synthetic lethality in human and cancer contexts, limitations of previous methods could be met with a

Table 1.2: Methods for Predicting Synthetic Lethality in Cancer

Method	Input Data	Source	Tool Offered
Network Centrality	protein-protein interactions	Kranthi <i>et al.</i> (2013)	
Differential Expression	Expression Mutation	Wang and Simon (2013)	
Comparative Genomics Chemical-Genomics	Yeast synthetic gene interactions Homology	Heiskanen and Aittokallio (2012)	
Comparative Genomics	Yeast synthetic gene interactions Homology	Deshpande <i>et al.</i> (2013)	
Machine Learning		Discussed by Babyak (2004) and Lee and Marcotte (2009)	
Differential Expression	Expression	Tiong <i>et al.</i> (2014)	
Literature Database		Li <i>et al.</i> (2014)	Syn-Lethality
Meta-Analysis	Meta-Analysis Machine Learning	Wu <i>et al.</i> (2014)	MetaSL
Pathway Analysis		Zhang <i>et al.</i> (2015)	
Protein Domains	Homology	Kozlov <i>et al.</i> (2015)	
Data-Mining Machine Learning	Expression Somatic mutation and DNA CNV siRNA in cell lines	Jerby-Arnon <i>et al.</i> (2014) Ryan <i>et al.</i> (2014) Crunkhorn (2014) Lokody (2014)	DAISY (method)
Genome Evolution Hypothesis Test Machine Learning	Expression DNA CNV Known SL	Lu <i>et al.</i> (2013) Lu <i>et al.</i> (2015)	
Bimodality	Expression DNA CNV Somatic Mutation	Wappett (2014) Wappett <i>et al.</i> (2016)	BiSEp
Directional Chi-Square	Expression (microarray) Somatic mutation	Kelly, S. T., Guilford, P. J., and Black, M. A. Dissertation (Kelly, 2013) and developed here	SLIPT

different approach. Existing computational approaches to synthetic lethal prediction are often difficult to interpret, replicate for new genes, or reliant on are data types not available for a wider range of genes to test.

### 1.2.7.2 Comparative genomics

A comparative genomics approach by Deshpande *et al.* (2013) used the results of well characterised high-throughput mutation screens in *S. cerevisiae* as candidates for synthetic lethality in humans (Baryshnikova *et al.*, 2010a; Costanzo *et al.*, 2010, 2011; Tong *et al.*, 2001, 2004). Yeast synthetic lethal partners were compared to human orthologues to find cancer relevant synthetic lethal candidate pairs with direct therapeutic potential. Proposed as a complementary approach to siRNA screens, approximately 24,000 of the 116,000 negative SGIs in yeast (Costanzo *et al.*, 2011) were matched to human orthologues, with over 500 involving a cancer gene (Futreal *et al.*, 2004). Under strict criteria of one-to-one orthologues, large effect size and significant interaction in

yeast data ( $\epsilon < -0.2$ ,  $p < 0.05$ ), 1,522 interactions were identified with 70 involving cancer genes. Of the 21 gene interactions tested with pairs of siRNA in IMR1 fibroblast cells, 6 exhibited synthetic lethal effects. The two strongest interactions (*SMARCB1* with *PSMA4* and *ASPSCR1* with *PSMC2*) were successfully validated in by protein analysis of human cells and replication with tetrad analysis for yeast orthologues.

Another approach to systematic synthetic lethality discovery specific to human cancer (in contrast to the plethora of yeast synthetic lethality data) was to build a database as done by Li *et al.* (2014). In their relational database, called “Syn-lethality”, they have curated both known experimentally discovered synthetic lethal pairs in humans (113 pairs) from the literature and those predicted from synthetic lethality between orthologous genes in *S. cerevisiae* yeast (1114 pairs). This knowledge-based database is the first dedicated to human cancer synthetic lethal interactions and integrates gene functional, annotation, pathway and molecular mechanism data with experimental and predicted synthetic lethal gene pairs. This combination of data sources is intended to tackle the trade-off between more conclusive synthetic lethal experiments in yeast and more clinically relevant synthetic lethal experiments in human cancer models, such as RNAi, especially when high-throughput screens are costly and prone to false positives in either system and difficult to replicate across gene backgrounds. This database centralises a wealth of knowledge scattered in the literature including cancer relevant genes (*BRCA1*, *BRCA2*, *PARP1*, *PTEN*, *VHL*, *MYC*, *EGFR*, *MSH2*, *KRAS*, and *TP53*) and is publicly available as a Java App. These included the previously mentioned interactions of *BRCA1* and *BRCA2* with *PARP1* and *TP53* with *WEE1* and *PLK1*. However, the computational methodology was not released, so it is not possible to replicate their results, nor to add to the findings with new datasets, which are limited to 647 human genes. Suggested future directions were promising, such as constructing networks of known synthetic lethality, applying known synthetic lethality to cancer treatment, data mining, replicating the approach for synthetic lethality in model organisms, signalling pathways, and develop a complete global network in human cancer or yeast (both of which are still incomplete with experimental data), some of which has been implemented in “SynLethDB” (Guo *et al.*, 2016).

Machine learning approaches have also been proposed for synthetic lethal discovery (Babyak, 2004; Lee and Marcotte, 2009). Due to concerns that these may be subject to overfitting or noise, Wu *et al.* (2014) developed a meta-analysis method (based on the machine learning methods in Table 1.3) for synthetic lethal gene pairs rele-

Table 1.3: Machine Learning Methods used by Wu *et al.* (2014)

Method	Source	Tool Offered
Random Forest	Breiman (2001)	
Random Forest	Hall <i>et al.</i> (2009)	WEKA
J48 (decision tree)		
Bayes (Log Regression)		
Bayes (Network)		
PART (Rule-based)		
RBF Network		
Bagging / Bootstrap		
Classification via Regression		
Support Vector Machine (Linear)	Vapnik (1995)	
Support Vector Machine (RBF – Gaussian)	Joachims (1999)	
Multi-Network Multi-Class (MNMC)	Pandey <i>et al.</i> (2010)	
MetaSL (Meta-Analysis)	Wu <i>et al.</i> (2014)	MetaSL

vant to developing selective drugs against human cancer, building upon their previous database (Li *et al.*, 2014). The used training data of 10,885 synthetic lethal interactions from yeast experiments of which 7347 occurred between the 5,504 non-essential genes. Their “metaSL” approach utilises genomic, proteomic and annotation data (including GO terms Ashburner *et al.* (2000), PPI, protein complexes, and biological pathway) with strong statistical performance in yeast data (AUROC of 0.871). The predicted orthologous synthetic lethal partners in human data were not experimentally validated but several would be relevant to cancer such as *EGFR* with *PRKCZ*. They note that computational approaches scale-up across the genome at lower cost than experimental screen and share their most supported interactions online. However, the method is not available for analysis of other genes studied by the cancer research community. While machine learning has great potential as a predictor, the results vary greatly depending on the predictive features selected and it is not clear which threshold should be used to report reliably detected genes. Syn-Lethality (Li *et al.*, 2014) and MetaSL (Wu *et al.*, 2014) demonstrate the value of computational approaches to synthetic lethality but omit many genes of importance in cancer, such as *CDH1*, and there remains a need to enable biological researchers to query such genes in a particular tissue or genetic background.

There is also concern for analyses based on yeast data that many synthetic lethal

interactions may not be conserved between species Dixon *et al.* (2009), although interactions between pathways may be more comparable. It is unsurprising that many of the interactions identified were not experimentally validated. There have been many gene duplications in the separate evolutionary histories of humans and yeast which may lead to differences in genetic redundancy. Yeast are further not an ideal human cancer model because they do not have tissue specificity, multicellular gene regulation, or orthologues to a number of known cancer genes such as p53. Although these studies have tried to anticipate these issues with stringent criteria such as requiring one-to-one orthologues, there remains the possibility that changes in gene function may affect whether these are solely redundant such as if functions had coevolved without sequence homology. Many genes will also be excluded by lacking homologous gene in yeast, the corresponding experimental data, or having paralogues in either species. Thus conservation of yeast interactions is not an ideal strategy and analysis of human data directly for comparison with human experimental data will be the focus of this thesis.

### 1.2.7.3 Analysis and modelling of protein data

Kranthi *et al.* (2013) took a network approach to discovery of synthetic lethal candidate selection applying the concept to “centrality” to a human PPI network involving interacting partners of known cancer genes. The effect of removing pairs of genes on connectivity of the network was used as a surrogate for viability which is supported by observations that the PPI and synthetic lethal networks are orthogonal in *S. cerevisiae* studies (Tong *et al.*, 2004). They showed that the human cancer protein interaction network (of 1539 proteins and 6471 interactions) exhibits the power law distribution expected of a scale-free synthetic lethal network with high connectivity (average vertex degree of 23.67 and network efficiency of 0.2952). Their top 100 candidate interactions included interactions of the tumour suppressor *TP53* with *BRCA1*, *CDKNA1*, *CDKNA2*, *MET*, and *RB1* which have been detected by prior studies. The gene pairs were often observed to be in the same or a plausible compensatory pathway. Thus the network structure is important in the biological functions of cancers and could be exploited for targeting *TP53* loss of function mutations.

However, their approach was limited to known cancer genes and is not applicable to genes that do not have PPI data. Other nucleotide sequencing data types are more commonly available for cancer studies at a genomic scale. Of further concern is that the results were enriched for p53 synthetic lethal partners which is relevant to many



cancer researchers but this genome-wide approach did not detect many other cancer genes due to multiple testing. This enrichment may be due to the known drastic effect of removing p53 itself from the network as a master regulator, cancer driving tumour suppressor gene, and highly connected network “hub”. The focus on cancer genes is useful for translation into therapeutics but does not account for variable genetic backgrounds or effect of protein removal on the whole cellular network.

Focusing on the potential for synthetic lethality to be an effective anti-cancer drug target, Zhang *et al.* (2015) used modelling of signalling pathways to identify synthetic lethal interactions between known drug targets and cancer genes by simulating gene knockdowns. A computational approach applied to avoid the limitations of experimental RNAi screens such as scale, instability of knockdown, and off-target effects. This ‘hybrid’ method of a data-driven model and known signalling pathways showed potential as a means to predict cell death in single and combination gene knockouts. They used time series protein phosphorylation data (Lee *et al.*, 2012) for 28 signalling proteins and Gene Ontology (GO) pathways Ashburner *et al.* (2000); Blake *et al.* (2015). This approach successfully detected many known essential genes in the human gene essentiality database, known synthetic lethal partners in the Syn-Lethality database (Li *et al.*, 2014), and predicted novel synthetic lethal gene pairs. The strongest essential genes in single knockdowns were *AKT*, *TP53*, *CHK1*, *S6K1*, and *CYCLIND1*. Pairwise knockdowns identified 252 candidate synthetic lethal interactions including *TP53* with *CHK1*, *S6K1*, *WEE1*, *CYCLIND1*, and *CASP9*; *AKT* with *WEE1*; and *CDK1* with *CYCLIND1*. These novel results contained many *TP53* and *AKT* synthetic lethal partners, genes known to be important in many cancers, however these also have a large impact on the signalling pathways in their essentiality analysis of single gene disruptions and large phenotypic changes in cancer. This approach is amenable to detect functionally related pathways and protein complexes across the molecular function, cellular component, and biological process annotations provided by GO. The results were consistent with the experimental results in the literature but the novel synthetic lethal interactions have yet to be validated. While the mathematical reasoning and algorithms are given, the code was not released to replicate the findings or apply the methodology beyond the signalling pathways analysed by Zhang *et al.* (2015). While this is an interesting approach, the analysis of this thesis will focus on gene expression and RNAi data which is available to test a wider range of candidate gene pairs.

#### 1.2.7.4 Differential gene expression

Differential gene expression has been explored to predict synthetic lethal pairs in cancer which would be widely applicable due to the availability of public gene expression data for a large number of samples and cancer types. Wang and Simon (2013) found differentially expressed genes (by the t-test, adjusted by FDR) between tumours with or without functional p53 mutations in TCGA (McLendon *et al.*, 2008) and Cell Line Encyclopaedia (CCLE) RNA-Seq gene expression data as candidate synthetic lethal partner pathways of p53. They identified 2, 8, and 21 candidate synthetic lethal partner genes in 3 microarray datasets from the NCI60 cell lines, 31 partner genes from the CCLE RNA-Seq data, and 50 in TCGA RNA-Seq data. *PLK1* was replicated across 4 of these analyses and 17 other genes were replicated across 2 analyses (including *MTOR*, *PLK4*, *MAST2*, *MAP3K4*, *AURKA*, *BUB1* and 6 CDK genes) with many playing a role in cell cycle regulation. This was supported by a drug sensitivity experiment on the NCI60 cell lines which found that cells which lacked functional p53 were more sensitive to paclitaxel (which targets *PLK1*, *AURKA*, and *BUB1*). This demonstrated the potential of gene expression as a surrogate for gene function and use of public genomic data to predict synthetic lethal gene pairs in cancer. Wang and Simon (2013) advocated for pre-screening of expression profiles to augment future RNAi screens. However, the analyses were limited to kinase genes and focused on currently druggable genes, lacking wider application of synthetic lethal prediction methodology. This approach may not be feasible or applicable in cancer genes with a lower mutation rate than p53.

Tiong *et al.* (2014) also investigated gene expression as a predictor of synthetic lethal pairs with colorectal cancer microarrays from a Han Chinese population with a sample size of 70 tumour and 12 normal tissue samples. Simultaneously differentially expression of “tumour dependent” gene pairs (which includes co-expression) between cancer and normal tissue was used to rank 663 candidate synthetic lethal interactions identified in cell line siRNA experiments. Of the top 20 genes, 17 were tested for testing differential expression at the protein level with immunohistochemistry staining and correlation with clinical characteristics, with 11 pairs exhibiting synergistic effects. Some of the predicted synthetic lethal pairs were consistent with the literature (including *TP53* with *S6K1* and partners of *KRAS*, *PTEN*, *BRCA1*, and *BRCA2*) and two novel synthetic lethal interactions (*TP53* with *CSNK1E* and *CTNNB1*) were validated in pre-clinical models. This serves a valuable proof-of-concept for integration of *in silico* approaches to synthetic lethal discovery in cancer demonstrating it’s utility to triage and identify synthetic lethal partners of p53 applicable to colorectal tissues.

Although the experimental work was the focus of the paper, these findings show that bioinformatics synthetic lethal candidates can be validated in patient tissue samples (from a non-caucasian population) to find those applicable to colorectal cancers.

#### 1.2.7.5 Data mining and machine learning

Recognising the utility of synthetic lethality to drug inhibition and specificity of anti-cancer treatments, Jerby-Arnon *et al.* (2014) also saw the need for effective prediction of gene essentiality and synthetic lethality to augment experimental studies of SL. They developed a data-driven pipeline called DAISY (data mining synthetic lethality identification pipeline) and tested for genome-wide analysis of synthetic lethality in public cancer genomics data from TCGA and CCLE. DAISY is intended to predict the candidate synthetic lethal partners of a query gene such as genes recurrently mutated in cancer.

Jerby-Arnon *et al.* (2014) combined a computational approach to triage candidates with a conventional RNAi screen to validate synthetic lethal partners. They screened a selection of computationally predicted candidates and randomly selected genes with RNAi against *VHL* loss of function mutation in RCC4 renal cell lines. The computational method had a high AUROC of 0.779 and predictions were enriched 4× for validated RNAi hits over randomly selected genes. This approach detected known synthetic lethal pairs such as *BRCA1* or *BRCA2* genes with *PARP1* and *MSH2* with *DHFR*. The synthetic lethal candidates identified with both RNAi screening and computational prediction formed an extensive network of 2077 genes with 2816 synthetic lethal interactions and similar network of 3158 genes with 3635 synthetic dosage lethal interactions (for synthetic lethality with over-expression). Each network was scale-free as expected of a biological network and was enriched for known cancer genes, essential genes in mice, and could be harnessed for predicting prognosis and drug response. While demonstrating the feasibility of combining experimental and computational approaches to synthetic lethality in cancer, there remain challenges in predicting synthetic lethal genes, novel drug targets, and translation into the clinic.

The DAISY methodology (Jerby-Arnon *et al.*, 2014) compares the results of analysis of several data types to predict synthetic lethality, namely: DNA copy number and somatic mutation for TCGA patient samples and CCLE cell lines. The cell lines were also analysed with gene expression and gene essentiality (shRNA screening) profiles. Genes were classed as inactivated by copy number deletion, somatic loss of function mutation, or low expression and tested for synthetic lethal gene partners which are ei-

ther essential in screens or not deleted with copy number variants. Co-expression is also used for synthetic lethality prediction based on studies in yeast (Costanzo *et al.*, 2010; Kelley and Ideker, 2005). Copy number, gene expression and, essentiality analyses are stringently compared by adjusting each for multiple tests with Bonferroni correction and only taking hits which occur in all analyses. This methodology was also adapted for synthetic dosage lethality by testing for partner genes where genes are overactive with high copy number or expression. As discussed above, the predictions performed well and an RNAi screen for the example of *VHL* in renal cancer validated predicted synthetic lethal partners of *VHL* demonstrating the feasibility of combining approaches to synthetic lethal discovery in cancer and using computational predictions to enable more efficient high-throughput screening. DAISY performs well statistically with a AUROC of 0.779 on a set of gene pairs with experimental screen data, although co-expression and shRNA functional examination contributes much less of this than the mutation and copy number analysis (AUROC 0.683 alone). However, this methodology is very stringent, missing potentially valuable synthetic lethal candidates, may not be applicable to genes of interest to other groups and the software for the procedure is not publicly released for replication.

Although the DAISY procedure performs well and has been well received by the scientific community (Crunkhorn, 2014; Lokody, 2014; Ryan *et al.*, 2014), showing a need for such methodology, there is no indication of adoption of the methodology in the community yet. The co-expression analysis may not be the most effective way to test gene expression for directional synthetic lethal interactions (where inverse correlation would be expected). In the interests of a large sample size, tissue types were not tested separately despite tissue-specific synthetic lethality being likely since gene function (and by extension expression, isoforms, and clinical characteristics) in cancers may often be tissue-dependent. Some data forms and analyses used, such as gene essentiality, may not be available for all cancers, genes, or tissues, and may not be reproduced.

Lu *et al.* (2015) critique the assumption of co-expression in the DAISY methodology and propose an alternative computational prediction of synthetic lethality based on machine learning methods and a cancer genome evolution hypothesis. Using DNA copy number and gene expression data from TCGA patient samples, a cancer genome evolution model assumes that synthetic lethal gene pairs behave in 2 distinct ways in response to an inactive synthetic lethal partner gene, either a “compensation” pattern where the other synthetic lethal partner is overactive or a “co-loss underrepresentation” pattern where the other synthetic lethal partner is less likely to be lost, since loss of

both genes would cause death of the cancer cell. During the cancer genome evolution as the cell becomes addicted to the remaining synthetic lethal partner due to induced gene essentiality. These patterns would explain why DAISY detects only a small number of synthetic lethal pairs, compared to the large number expected based on model organism studies (Boone *et al.*, 2007), and the disparity between screening and computationally predicted synthetic lethal candidates due to testing different classes of synthetic lethal gene pairs.

Lu *et al.* (2015) compared a genome-wide computational model of genome evolution and gene expression patterns to the experimental data of Vizeacoumar *et al.* (2013) and Laufer *et al.* (2013). This simpler model performing well with an AUROC of 0.751 but was less than DAISY, although it did not rely on data from cell lines which may not represent patient disease. They predict a larger comprehensive list of 591,000 human synthetic lethal partners with a probability score threshold of 0.81, giving a precision of 67% and 14 $\times$  enrichment of synthetic lethal true positives compared to randomly selected gene pairs. Discovery of such a vast number of cancer-relevant synthetic lethal interactions in humans would not be feasible experimentally and is a valuable resource for research and clinical applications. These predictions are not limited by assuming co-expression of synthetic lethal partners or evolutionary conservation with model organisms enabling wider synthetic lethal discovery. However, there remains a lack of basis for an expectation of how many synthetic lethal partners a particular gene will have, how many pairs there are in the human genome, and whether pathways or correlation structure would influence predicted synthetic lethal partners.

Large scale, computational approaches have yet to determine whether synthetic lethal interactions are tissue-specific since Lu *et al.* (2015) used pan-cancer data for 14136 patients with 31 cancer types. Experimental data used for comparison was a small training dataset specific to colorectal cancer, and based on screens for other phenotypes, which may limit performance of the model or application to other cancers. Proposed expansion of the computational approach to mutation, microRNA, or epigenetic modulation of gene function and tumour micro-environment or heterogeneity suggests that synthetic lethal discovery could be widely applied to the current challenges in cancer genomics. This approach was also based on machine learning methodology and not supported by a software released for the community to develop, contribute to, or reproduce beyond the gene pairs given in the supplementary results.

### 1.2.7.6 Bimodality

Wappett *et al.* (2016) demonstrate a multi-omic approach to identification of synthetic lethality in cancer with a strategy to detect bimodal patterns in molecular profiles. The release this solution as the Bimodal Subsetting Expression (BiSEp) R package Wappett (2014) which aims to detect subtle bimodal and non-normal patterns in expression data. Since loss of gene function is not consistently genetic, Wappett *et al.* (2016) advocate the use of gene expression (loss of mRNA) and deletion (loss of copy number) data in addition to mutation. The BiSEp procedure was demonstrate on an analysis of 881 cell lines from CCLE (Barretina *et al.*, 2012), 442 cell lines from COSMIC (Forbes *et al.*, 2015), and RSEM normalised RNA-Seq data for 178 TCGA lung patient samples (Collisson *et al.*, 2014). BiSEp was demonstrated to have significant enrichment of validated tumour suppressor, synthetic lethal gene pairs (detecting 76 experimentally supported gene pairs) and was improved (detecting 420) with expression data rather than relying on detecting loss of gene function by mutation or deletion. They identified interactions with genes relevant to cancer with support in experimental screens including *ERCC4* with *XRCC1*, *BRCA1* with *PARP3*, and *SMARCA1* with *SMARCA4*.

Wappett *et al.* (2016) demonstrated that analysis of genomics data, particularly expression data, is relevant to augment the identification of synthetic lethal interactions with screening experiments. They further show that this is applicable in both genetically homogenous cell lines and heterogeneous cell population from patient samples. This approach is limited however to genes which exhibit bimodal expression patterns which do not commonly occur, particularly in normalised gene expression data, and other approaches may need to be considered for gene such as *CDH1* which were not identified by BiSEp.

### 1.2.7.7 Rationale for further development

Many of the approaches discussed here aimed to identify the strongest synthetic lethal pairs across the yeast of human genome (Deshpande *et al.*, 2013; Lu *et al.*, 2015; Wappett *et al.*, 2016; Wu *et al.*, 2014), which may not be an ideal strategy to identify interactions in particular functions or relevance to particular cancers. These demonstrate a need for computational approaches to prioritise candidate gene pairs for validation but this thesis will focus on the interactions with *CDH1* with particular importance in breast and stomach cancers, although these partners may be applicable in other can-

cers. As such, this thesis presents a query-based method, amenable to identification of candidate partners for a selected gene of functional or translational importance such as *CDH1*.

## 1.3 E-cadherin as a Synthetic Lethal Target

E-cadherin is a transmembrane protein (encoded by *CDH1*) with several characterised functions in the cytoskeleton and cell-to-cell signaling. Here we outline the key known functions of E-cadherin and its importance in cancer biology. *CDH1* is a tumour suppressor gene, with loss of function occurring in both familial (germline mutations) and sporadic (somatic mutations) cancers. As such, *CDH1* inactivation is a prime example of a genetic event that could be targeted by synthetic lethality for anti-cancer treatments. Most notably this includes patients at risk of developing hereditary breast and stomach cancers for which conventional surgical or cytotoxic chemotherapy is not ideal (due to impact of quality of life) and who have a known genetic aberration in their familial syndromic cancers. Effective treatments against *CDH1* inactivation would also benefit patients with sporadic diffuse gastric cancers since they often present with symptoms at a late stage.

### 1.3.1 The *CDH1* gene and its Biological Functions

The tumour suppressor gene *CDH1* is implicated in hereditary and sporadic lobular breast cancers (Berx *et al.*, 1996; Berx and van Roy, 2009; De Leeuw *et al.*, 1997; Masciari *et al.*, 2007; Semb and Christofori, 1998; Vos *et al.*, 1997). The *CDH1* gene encodes the E-cadherin protein and is normally expressed in epithelial tissues, where it has also been identified as an invasion suppressor and loss of *CDH1* function has been implicated in breast cancer progression and metastasis (Becker *et al.*, 1994; Berx *et al.*, 1995; Christofori and Semb, 1999).

#### 1.3.1.1 Cytoskeleton

The primary function of *CDH1* is cell-cell adhesion forming the adherens junction, maintaining the cytoskeleton and mediating molecular signals between cells. The function of the adherens complex is particularly important for cell structure and regulation because it interacts with cytoskeletal actins and microtubules. The cytoskeletal role of E-cadherin maintains healthy cellular viability and growth in epithelial tissues in-

cluding cellular polarity. E-cadherin is not essential to cellular viability but loss in epithelial cells does lead to defects in cytoskeletal structure and proliferation. In addition to a central role in the adherens complex, E-cadherin is involved in many other cellular functions and thus *CDH1* is regarded as a highly pleiotropic gene.

#### **1.3.1.2 Extracellular and Tumour Micro-Environment**

As a transmembrane signaling protein E-cadherin also interacts with the extracellular environment and other cells, most notably forming tight junctions between cells. These junctions serve to both regulate movement of ion signals between cells and separate membrane proteins on the apical and basal surfaces of a cell, maintaining cell polarity. Thus E-cadherin is an important regulator of epithelial tissues by intercellular communication. It also has important roles in the extracellular matrix, including fibrin clot formation. The role of intercellular interactions and the tissue micro-environment are important themes in cancer research, being a potential mechanism for cancer progression and malignancy in a addition to it's potential for specifically targeting tumour cells.

#### **1.3.1.3 Cell-Cell Adhesion and Signalling**

The signals mediated by tight junctions are also passed on to intracellular signalling pathways and thus E-cadherin also has a role in maintaining cellular function and growth. One such example is the regulation of  $\beta$ -catenin which interacts with both the actin cytoskeleton and acts as a transcription factor via the WNT pathway. Similarly, the HIPPO and PI3K/AKT pathways are implicated in being mediated by E-cadherin, having roles in promoting cell survival, proliferation, and repressing apoptosis. E-cadherin shares several downstream pathways with signaling pathways such as integrins and thus indirectly interacts with them, particularly since feedback loops may occur in such pathways. Conversely, the multifaceted roles of E-cadherin have been shown with differing overexpression in ovarian cells promoting tumour growth, while it maintains healthy cellular functions in other cells.

### **1.3.2 *CDH1* as a Tumour (and Invasion) Suppressor**

E-cadherin has key roles in maintaining cellular structure and regulating growth, consistent with *CDH1* being a tumour suppressor gene. Loss of *CDH1* in epithelial tissues leads to disrupted cell polarity, differentiation, and migration. E-cadherin loss has



been identified as a recurrent driver tumour suppressor mutation in sporadic cancers of many tissues including breast, stomach, lung, colon, and pancreas tissue.

### 1.3.2.1 Breast Cancers and Invasion

E-cadherin loss in breast cancers has been shown to cause increased proliferation, lymph node invasion, and metastasis with poor cell-cell contact. Thus *CDH1* gene has also been implicated as an invasion suppressor, with a key role in the epithelial-mesenchymal transition (EMT), an established mechanism of cancer progression (Hanahan and Weinberg, 2011). The epithelial-mesenchymal transition is important during development and wound healing but such changes in cellular differentiation also occur in cancers. If *CDH1* is inactivated by mutation or DNA methylation (Berx *et al.*, 1996; Guilford, 1999; Machado *et al.*, 2001), it is likely that EMT will drive growth of E-cadherin deficient cancers (Berx and van Roy, 2009; Graziano *et al.*, 2003; Polyak and Weinberg, 2009). While loss of E-cadherin is not sufficient to cause EMT or tumourigenesis, it is an important step in this mechanism of tumour progression and a potential therapeutic intervention may therefore also impede cancer progression and have activity against advanced stage cancers.

### 1.3.3 Hereditary Diffuse Gastric Cancer and Lobular Breast Cancer

*CDH1* loss of function mutations also causes familial cancers, including diffuse gastric cancer and lobular breast cancer (Graziano *et al.*, 2003; Guilford *et al.*, 2010, 1999; Oliveira *et al.*, 2009). Individuals carrying a null mutation in *CDH1* have a syndromic predisposition to early-onset these cancers, known as Hereditary Diffuse Gastric Cancer (HDGC) (Guilford *et al.*, 1998). Due to the loss of an allele, these individuals are prone to carcinogenic lesion in the breast and stomach when the other allele is inactivated, occurring much more frequently and thus younger than in individuals without a second functional allele of *CDH1*. The loss of the second allele is most often hypermethylation suppressing expression rather than mutation, although loss of heterozygosity may also occur. Therefore HDGC is an autosomal dominant cancer syndrome with incomplete penetrance. The “lifetime” (until age 80 years) risk for mutation carriers of diffuse gastric cancer is 70% in males and 56% in females. In addition, the lifetime risk of lobular breast cancer is 42% in female mutation carriers.

HDGC affects less than 1 in a million people globally (Ferlay *et al.*, 2015) and

less than 1% of gastric cancers. However, HDGC is documented to affect several hundred families globally. E-cadherin mutations in the germline is implicated in 1-3% of gastric cancers presenting with a family history, varying between high and low incidence populations. E-cadherin is also mutated in 13% of sporadic gastric cancers.

While diagnostic testing for *CDH1* genotype has enabled more effective management of HDGC and improved patient outcomes, there are still limited options for clinical interventions (Guilford *et al.*, 2010). Individuals with a family history of HDGC are recommended to be tested for *CDH1* mutations in late adolescence and are offered prophylactic stomach surgery before the risk of developing cancers increases with age. Another option is annual endoscopic screening to diagnose early stage stomach cancers with surgical intervention once they are detected (Oliveira *et al.*, 2013). However, these early stage cancers are difficult to detect and may be missed in regular screening. Thus patients carrying *CDH1* mutations either have surgical interventions with a significant impact on quality of life and risk of complications or remain at risk of developing advanced stage stomach cancers. Due to the lower mortality rate due to stomach cancers, there is increasing concerns among these HDGC families on the elevated risk of lobular breast cancers for women later in life.

The current clinical management of HDGC still has significant risks for patients and therefore a greater understanding of the molecular and cellular function of *CDH1* is important for its role in these cancers. Such studies may lead to alternative treatment strategies such as pharmacological treatments with specificity against *CDH1* null cells, once they lose the second allele. While a loss of gene function cannot be targeted directly, designing a treatment with specificity against *CDH1* may also have activity in sporadic cancers in a range of epithelial cancers. Thus an effective treatment against *CDH1* mutant cancers would potentially have significant therapeutic and preventative applications in a large number of patients.

## 1.3.4 Somatic Mutations

### 1.3.4.1 Mutation Rate

Estimates for the prevalence of *CDH1* somatic mutations in sporadic cancers varies. The Cancer Gene Census (Futreal *et al.*, 2004; Pleasance *et al.*, 2010) detected 994 distinct mutations in 10,143 tumour samples (at a rate of 7.52%), COSMIC (2016) detected 632 distinct mutations in 43,865 tumour samples (at a rate of 1.71%), and the NCI60 detected mutations in 13.2% of 53 cancer cell lines. While there is no consensus

on the prevalence of *CDH1* mutations, the vast variability of mutations is consistent with its role as a tumour suppressor and it has been found to be recurrently mutated in a wide range of cancers of epithelial tissues.

COSMIC (2016) reports *CDH1* mutations in 40 cancer tissue types including stomach (11.40% in N=1342), breast (10.29% in N=3343), large colon (2.87%), skin (2.83%), endometrial (2.81%), and bladder (1.9%) cancer. ICGC reports *CDH1* mutations in 29 cancer tissue types including skin (23.41% in N=598), breast (14.50% in N=1696), ovary (13.98%, N=93), and stomach (11.41% in N=289) cancer samples. *CDH1* mutations are reported at similar rates in breast and stomach cancer in other cancer genomics projects and studies across distinct populations. cBioPortal reports *CDH1* mutation prevalence in stomach cancer at 16.7% (Tokyo Univ., Kakiuchi, 2014, N=30), 15% (Pfizer/UHK, Wang, 2014, N=100), 14.1% (Tianjin Medical University, Chen, 2015, N=78), and 9.4% (TCGA, 2017 prov, N=393). cBioPortal also reports *CDH1* mutation prevalence in breast cancer at 12.7% (TCGA, 2017 prov, N=963) and 10.8% (METABRIC, 2012/2016, N=2051). The rare plasmacytoid bladder cancer subtype also has a high prevalence of *CDH1* mutations in COSMIC (2016) at a rate of 81.8% (N=33). These demonstrate that *CDH1* is important in many cancers and targeting *CDH1* may be widely applied against sporadic cancers in addition to hereditary cancers. However, some of these studies have focused on disease subgroups (such as lobular subtype or estrogen receptor negative breast cancers) with poor patient outcomes which may have inflated the prevalence of *CDH1* mutations which are more common in some of these subtypes.

### 1.3.4.2 Co-occurring Mutations

Another concern is that *CDH1* mutations may co-occur with other known cancer driver genes such as highly prevalent tumour suppressor gene *TP53* or the proto-oncogene *PIK3CA*. cBioPortal reports the prevalence of the mutations in these genes at 10% for *CDH1*, 49% for *TP53*, 22% for *PIK3CA* in stomach cancer (TCGA, 2017 prov, N=393). There is no evidence of significant co-occurring mutations between *CDH1* and *PIK3CA* (mutex  $p = 0.231$ ) but there is evidence for significant mutually exclusive mutations for *CDH1* (mutex  $p = 0.002$ ) and *PIK3CA* (mutex  $p = 0.004$ ) with *TP53*. cBioPortal also reports the prevalence of the mutations in these genes at 13% for *CDH1*, 32% for *TP53*, 36% for *PIK3CA* in breast cancer (TCGA, 2017 prov, N=3963). There is evidence of significant co-occurring mutations with *CDH1* and *PIK3CA* (mutex  $p < 0.0001$ ) and evidence for significant mutually exclusive mutations for *CDH1* (mutex  $p = 0.003$ ) and

*PIK3CA* (mutex  $p = 0.032$ ) with *TP53*.

These cancer driver mutations have distinct molecular features, leading to disease progression in distinct ways which is a concern for drug resistance when several mutations may accumulate, particularly for sporadic cancers where this is common. Targeting *CDH1* specifically is most suitable for hereditary cancers and combination therapies may be required for sporadic cancers. However, *CDH1* and *TP53* mutant cancers appear to be distinct pathways of tumour progression so the high impact of *TP53* mutation on cancer cells need not be considered for the purposes of studying *CDH1*.

### 1.3.5 Models of *CDH1* loss in cell lines

Previous work our research group has published used a model of homozygous *CDH1*<sup>-/-</sup> null mutation in non-malignant MCF10A breast cells to show that loss of *CDH1* alone was not sufficient to induce EMT with compensatory changes in the expression of other cell adhesion genes occurring (Chen *et al.*, 2014). However, *CDH1* deficient cells did manifest changes in morphology, migration, and weaker cell adhesion (Chen *et al.*, 2014).

This *CDH1*<sup>-/-</sup> MCF10A model has been used in a genome-wide screen of 18,120 genes using small interfering RNAs (siRNA) and a complementary drug screen using 4,057 compounds to identify synthetic lethal partners to E-cadherin (Telford *et al.*, 2015). One of the strongest candidate pathways identified by Telford *et al.* (2015) were the GPCR signalling cascades, which were highly enriched by Gene Ontology analysis of the candidate synthetic lethal partners the primary siRNAs screen. This was supported by validation with Pertussis toxin, known to target G<sub>αi</sub> signalling (Clark, 2004), as were various candidate cytoskeletal pathways by inhibition of Janus kinase (JAK/STAT) and aurora kinase. The drug screen also produced candidates in histone deacetylase (HDAC) and phosphoinositide 3-kinase (PI3K) which were supported by validation and time course experiments.

## 1.4 Summary and Research Direction of Thesis

Genomics technologies and the data made available from them have great potential for understanding of genetics and improving healthcare, including identification of genes altered in cancer for molecular diagnosis, prognostic biomarkers, and therapeutic targets. This has been demonstrated with the identification of cancer genes in many cancers,

distinguishing tumour subtypes by expression profiles, and the development of targeted therapies against oncogenes (such as *BRAF* and tumour suppressors (such as *BRCA1*). Synthetic lethality is an important genetic interaction to study fundamental cellular functions and exploit them for biomarkers and cancer treatment. They present a means to target loss of function mutations and genetic dysregulation in tumour suppressor genes by identifying interacting partners with redundant or compensating molecular functions.

*CDH1* (encoding E-cadherin) is an example of a tumour suppressor gene implicated in sporadic breast and stomach cancers. Germline mutations in *CDH1* are also found in many patients with familial early onset cancers (HDGC). Discovery of synthetic lethal partners would be contribute to an understanding on the molecular mechanisms driving the growth of *CDH1* deficient tumours and identification of potential therapeutic targets or chemopreventative agents for management of HDGC. The clinical potential of the synthetic lethal approach has been demonstrated with the application of olaparib against *BRCA1* and *BRCA2* mutations Lord *et al.* (2015) but there remains the need to systematically identify synthetic lethal partner genes for other tumour suppressors such as *CDH1*. A synthetic lethal screen has been conducted on breast cell lines Telford *et al.* (2015) but computational approaches to identification of synthetic lethal partners of *CDH1* remains to be done.

While there are a wide range of experimental and computational approaches to synthetic lethal discovery, many are limited to particular applications, prone to false positives, inconsistent across independent approaches, or enriched for particular genes of interest. Therefore synthetic lethal interactions are difficult to replicate or apply in the clinic. Computational approaches to synthetic lethality are not widely adopted by the cancer research community and experimental approaches cannot be combined to study synthetic lethality at a genome-wide scale. However, these show interest in synthetic lethal discovery in the community and the need for robust predictions of synthetic lethal interactions in cancer and human tissues.

To address the concerns raised by recent computational approaches to synthetic lethal discovery in cancer (Jerby-Arnon *et al.*, 2014; Lu *et al.*, 2015; Wappett *et al.*, 2016), I present similar analysis using solely gene expression data which is widely available for a large number of samples in many different cancers. This uses a statistical methodology the Synthetic Lethal Interaction Prediction Tool (SLIPT) developed for this purpose. To further determine the limitations and implications of synthetic lethal predictions, modelling and simulation was performed upon the statistical behaviour

of synthetic lethal gene pairs in genomics data. Comparison of synthetic lethal gene candidates from public data analysis and experimental candidates, pathway analysis, and networks structure will also be presented to investigate the relationships between synthetic lethal candidates. Release of R codes used for simulation, prediction, and analysis will enable adoption of the methodology in the cancer research community and comparison to existing methods.

My thesis aims to develop such predictions for synthetic lethal partner genes with a focus on the example of E-cadherin to compare to the findings of Telford *et al.* (2015), develop of network approaches for pathway structure, and simulate gene expression on pathway structure with the following bioinformatics and computational biology investigations:

- Developed a query-based synthetic lethal detection methodology (SLIPT) for use on gene expression data
- Adapt this methodology to utilise somatic mutation for query genes or candidate pathway metagenes
- Apply Synthetic lethal prediction to public breast cancer genomics data from TCGA (TCGA, 2012)
- Identify over-represented biological pathways using Reactome (Croft *et al.*, 2014) among synthetic lethal candidate partner genes
- Compare these at the gene and pathway level to experimental screen data in breast cell lines from Telford *et al.* (2015)
- Replicate these analyses in stomach cancer genomics data from TCGA (Bass *et al.*, 2014)
- Determine whether synthetic lethal candidates have importance in biological networks of candidate partner pathways
- Determine whether there are relationships within biological network structures between experimental and predicted gene candidate partners
- Develop a statistical model of synthetic lethal gene expression
- Simulate gene expression with synthetic lethal genes and pathway structures

- Evaluate the effects of modification to the SLIPT procedure on its statistical performance
- Compare the statistical performance of the SLIPT procedure to alternative statistical methods
- Release a synthetic lethal prediction methodology (SLIPT) to the research community for wider application

# References

- Aarts, M., Bajrami, I., Herrera-Abreu, M.T., Elliott, R., Brough, R., Ashworth, A., Lord, C.J., and Turner, N.C. (2015) Functional genetic screen identifies increased sensitivity to wee1 inhibition in cells with defects in fanconi anemia and hr pathways. *Mol Cancer Ther*, **14**(4): 865–76.
- Abeshouse, A., Ahn, J., Akbani, R., Ally, A., Amin, S., Andry, C.D., Annala, M., Aprikian, A., Armenia, J., Arora, A., *et al.* (2015) The Molecular Taxonomy of Primary Prostate Cancer. *Cell*, **163**(4): 1011–1025.
- Adamski, M.G., Gumann, P., and Baird, A.E. (2014) A method for quantitative analysis of standard and high-throughput qPCR expression data based on input sample quantity. *PLoS ONE*, **9**(8): e103917.
- Agarwal, S., Deane, C.M., Porter, M.A., and Jones, N.S. (2010) Revisiting date and party hubs: Novel approaches to role assignment in protein interaction networks. *PLoS Comput Biol*, **6**(6): e1000817.
- Agrawal, N., Akbani, R., Aksoy, B.A., Ally, A., Arachchi, H., Asa, S.L., Auman, J.T., Balasundaram, M., Balu, S., Baylin, S.B., *et al.* (2014) Integrated genomic characterization of papillary thyroid carcinoma. *Cell*, **159**(3): 676–690.
- Akbani, R., Akdemir, K.C., Aksoy, B.A., Albert, M., Ally, A., Amin, S.B., Arachchi, H., Arora, A., Auman, J.T., Ayala, B., *et al.* (2015) Genomic Classification of Cutaneous Melanoma. *Cell*, **161**(7): 1681–1696.
- American Cancer Society (2017) Genetics and cancer. <https://www.cancer.org/cancer/cancer-causes/genetics.html>. Accessed: 22/03/2017.
- American Society for Clinical Oncology (ASCO) (2017) The genetics of cancer. <http://www.cancer.net/navigating-cancer-care/cancer-basics/genetics/genetics-cancer>. Accessed: 22/03/2017.



- Ashburner, M., Ball, C.A., Blake, J.A., Botstein, D., Butler, H., Cherry, J.M., Davis, A.P., Dolinski, K., Dwight, S.S., Eppig, J.T., *et al.* (2000) Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. *Nat Genet*, **25**(1): 25–29.
- Ashworth, A. (2008) A synthetic lethal therapeutic approach: poly(adp) ribose polymerase inhibitors for the treatment of cancers deficient in dna double-strand break repair. *J Clin Oncol*, **26**(22): 3785–90.
- Audeh, M.W., Carmichael, J., Penson, R.T., Friedlander, M., Powell, B., Bell-McGuinn, K.M., Scott, C., Weitzel, J.N., Oaknin, A., Loman, N., *et al.* (2010) Oral poly(adp-ribose) polymerase inhibitor olaparib in patients with brca1 or brca2 mutations and recurrent ovarian cancer: a proof-of-concept trial. *Lancet*, **376**(9737): 245–51.
- Babyak, M.A. (2004) What you see may not be what you get: a brief, nontechnical introduction to overfitting in regression-type models. *Psychosom Med*, **66**(3): 411–21.
- Bamford, S., Dawson, E., Forbes, S., Clements, J., Pettett, R., Dogan, A., Flanagan, A., Teague, J., Futreal, P.A., Stratton, M.R., *et al.* (2004) The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website. *Br J Cancer*, **91**(2): 355–358.
- Barabási, A.L. and Albert, R. (1999) Emergence of scaling in random networks. *Science*, **286**(5439): 509–12.
- Barabási, A.L. and Oltvai, Z.N. (2004) Network biology: understanding the cell’s functional organization. *Nat Rev Genet*, **5**(2): 101–13.
- Barrat, A. and Weigt, M. (2000) On the properties of small-world network models. *The European Physical Journal B - Condensed Matter and Complex Systems*, **13**(3): 547–560.
- Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A.A., Kim, S., Wilson, C.J., Lehar, J., Kryukov, G.V., Sonkin, D., *et al.* (2012) The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. *Nature*, **483**(7391): 603–607.

- Baryshnikova, A., Costanzo, M., Dixon, S., Vizeacoumar, F.J., Myers, C.L., Andrews, B., and Boone, C. (2010a) Synthetic genetic array (sga) analysis in *saccharomyces cerevisiae* and *schizosaccharomyces pombe*. *Methods Enzymol*, **470**: 145–79.
- Baryshnikova, A., Costanzo, M., Kim, Y., Ding, H., Koh, J., Toufighi, K., Youn, J.Y., Ou, J., San Luis, B.J., Bandyopadhyay, S., *et al.* (2010b) Quantitative analysis of fitness and genetic interactions in yeast on a genome scale. *Nat Meth*, **7**(12): 1017–1024.
- Bass, A.J., Thorsson, V., Shmulevich, I., Reynolds, S.M., Miller, M., Bernard, B., Hinoue, T., Laird, P.W., Curtis, C., Shen, H., *et al.* (2014) Comprehensive molecular characterization of gastric adenocarcinoma. *Nature*, **513**(7517): 202–209.
- Bateson, W. and Mendel, G. (1909) *Mendel's principles of heredity*, by W. Bateson. University Press, Cambridge [Eng.].
- Beck, T.F., Mullikin, J.C., and Biesecker, L.G. (2016) Systematic Evaluation of Sanger Validation of Next-Generation Sequencing Variants. *Clin Chem*, **62**(4): 647–654.
- Becker, K.F., Atkinson, M.J., Reich, U., Becker, I., Nekarda, H., Siewert, J.R., and Hfler, H. (1994) E-cadherin gene mutations provide clues to diffuse type gastric carcinomas. *Cancer Research*, **54**(14): 3845–3852.
- Bell, D., Berchuck, A., Birrer, M., Chien, J., Cramer, D., Dao, F., Dhir, R., DiSaia, P., Gabra, H., Glenn, P., *et al.* (2011) Integrated genomic analyses of ovarian carcinoma. *Nature*, **474**(7353): 609–615.
- Berx, G., Cleton-Jansen, A.M., Nollet, F., de Leeuw, W.J., van de Vijver, M., Cornelisse, C., and van Roy, F. (1995) E-cadherin is a tumour/invasion suppressor gene mutated in human lobular breast cancers. *EMBO J*, **14**(24): 6107–15.
- Berx, G., Cleton-Jansen, A.M., Strumane, K., de Leeuw, W.J., Nollet, F., van Roy, F., and Cornelisse, C. (1996) E-cadherin is inactivated in a majority of invasive human lobular breast cancers by truncation mutations throughout its extracellular domain. *Oncogene*, **13**(9): 1919–25.
- Berx, G. and van Roy, F. (2009) Involvement of members of the cadherin superfamily in cancer. *Cold Spring Harb Perspect Biol*, **1**: a003129.

- Bitler, B.G., Aird, K.M., Garipov, A., Li, H., Amatangelo, M., Kossenkov, A.V., Schultz, D.C., Liu, Q., Shih, Ie, M., Conejo-Garcia, J.R., *et al.* (2015) Synthetic lethality by targeting ezh2 methyltransferase activity in arid1a-mutated cancers. *Nat Med*, **21**(3): 231–8.
- Blake, J.A., Christie, K.R., Dolan, M.E., Drabkin, H.J., Hill, D.P., Ni, L., Sitnikov, D., Burgess, S., Buza, T., Gresham, C., *et al.* (2015) Gene Ontology Consortium: going forward. *Nucleic Acids Res*, **43**(Database issue): D1049–1056.
- Boettcher, M., Lawson, A., Ladenburger, V., Fredebohm, J., Wolf, J., Hoheisel, J.D., Frezza, C., and Shlomi, T. (2014) High throughput synthetic lethality screen reveals a tumorigenic role of adenylate cyclase in fumarate hydratase-deficient cancer cells. *BMC Genomics*, **15**: 158.
- Boone, C., Bussey, H., and Andrews, B.J. (2007) Exploring genetic interactions and networks with yeast. *Nat Rev Genet*, **8**(6): 437–49.
- Boucher, B. and Jenna, S. (2013) Genetic interaction networks: better understand to better predict. *Front Genet*, **4**: 290.
- Breiman, L. (2001) Random forests. *Machine Learning*, **45**(1): 5–32.
- Bryant, H.E., Schultz, N., Thomas, H.D., Parker, K.M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N.J., and Helleday, T. (2005) Specific killing of brca2deficient tumours with inhibitors of polyadprbose polymerase. *Nature*, **434**(7035): 913–7.
- Burk, R.D., Chen, Z., Saller, C., Tarvin, K., Carvalho, A.L., Scapulatempo-Neto, C., Silveira, H.C., Fregnani, J.H., Creighton, C.J., Anderson, M.L., *et al.* (2017) Integrated genomic and molecular characterization of cervical cancer. *Nature*, **543**(7645): 378–384.
- Bussey, H., Andrews, B., and Boone, C. (2006) From worm genetic networks to complex human diseases. *Nat Genet*, **38**(8): 862–3.
- Butland, G., Babu, M., Diaz-Mejia, J.J., Bohdana, F., Phanse, S., Gold, B., Yang, W., Li, J., Gagarinova, A.G., Pogoutse, O., *et al.* (2008) esga: E. coli synthetic genetic array analysis. *Nat Methods*, **5**(9): 789–95.
- Cancer Research UK (2017) Family history and cancer genes. <http://www.cancerresearchuk.org/about-cancer/>

- causes-of-cancer/inherited-cancer-genes-and-increased-cancer-risk/family-history-and-inherited-cancer-genes. Accessed: 22/03/2017.
- cBioPortal for Cancer Genomics (cBioPortal) (2017) cBioPortal for Cancer Genomics. <http://www.cbioportal.org/>. Accessed: 26/03/2017.
- Chen, A., Beetham, H., Black, M.A., Priya, R., Telford, B.J., Guest, J., Wiggins, G.A.R., Godwin, T.D., Yap, A.S., and Guilford, P.J. (2014) E-cadherin loss alters cytoskeletal organization and adhesion in non-malignant breast cells but is insufficient to induce an epithelial-mesenchymal transition. *BMC Cancer*, **14**(1): 552.
- Chen, S. and Parmigiani, G. (2007) Meta-analysis of BRCA1 and BRCA2 penetrance. *J Clin Oncol*, **25**(11): 1329–1333.
- Cherniack, A.D., Shen, H., Walter, V., Stewart, C., Murray, B.A., Bowlby, R., Hu, X., Ling, S., Soslow, R.A., Broaddus, R.R., *et al.* (2017) Integrated Molecular Characterization of Uterine Carcinosarcoma. *Cancer Cell*, **31**(3): 411–423.
- Chipman, K. and Singh, A. (2009) Predicting genetic interactions with random walks on biological networks. *BMC Bioinformatics*, **10**(1): 17.
- Christofori, G. and Semb, H. (1999) The role of the cell-adhesion molecule e-cadherin as a tumour-suppressor gene. *Trends in Biochemical Sciences*, **24**(2): 73 – 76.
- Ciriello, G., Gatza, M.L., Beck, A.H., Wilkerson, M.D., Rhie, S.K., Pastore, A., Zhang, H., McLellan, M., Yau, C., Kandoth, C., *et al.* (2015) Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer. *Cell*, **163**(2): 506–519.
- Clark, M.J. (2004) Endogenous Regulator of G Protein Signaling Proteins Suppress G  $\alpha$ -Dependent  $\mu$ -Opioid Agonist-Mediated Adenylyl Cyclase Supersensitization. *Journal of Pharmacology and Experimental Therapeutics*, **310**(1): 215–222.
- Clough, E. and Barrett, T. (2016) The Gene Expression Omnibus Database. *Methods Mol Biol*, **1418**: 93–110.
- Collins, F.S. and Barker, A.D. (2007) Mapping the cancer genome. Pinpointing the genes involved in cancer will help chart a new course across the complex landscape of human malignancies. *Sci Am*, **296**(3): 50–57.
- Collins, F.S., Morgan, M., and Patrinos, A. (2003) The Human Genome Project: lessons from large-scale biology. *Science*, **300**(5617): 286–290.

- Collisson, E., Campbell, J., Brooks, A., Berger, A., Lee, W., Chmielecki, J., Beer, D., Cope, L., Creighton, C., Danilova, L., *et al.* (2014) Comprehensive molecular profiling of lung adenocarcinoma. *Nature*, **511**(7511): 543–550.
- Corcoran, R.B., Ebi, H., Turke, A.B., Coffee, E.M., Nishino, M., Cogdill, A.P., Brown, R.D., Della Pelle, P., Dias-Santagata, D., Hung, K.E., *et al.* (2012) Egfr-mediated reactivation of mapk signaling contributes to insensitivity of braf-mutant colorectal cancers to raf inhibition with vemurafenib. *Cancer Discovery*, **2**(3): 227–235.
- Costanzo, M., Baryshnikova, A., Bellay, J., Kim, Y., Spear, E.D., Sevier, C.S., Ding, H., Koh, J.L., Toufighi, K., Mostafavi, S., *et al.* (2010) The genetic landscape of a cell. *Science*, **327**(5964): 425–31.
- Costanzo, M., Baryshnikova, A., Myers, C.L., Andrews, B., and Boone, C. (2011) Charting the genetic interaction map of a cell. *Curr Opin Biotechnol*, **22**(1): 66–74.
- Creighton, C.J., Morgan, M., Gunaratne, P.H., Wheeler, D.A., Gibbs, R.A., Robertson, A., Chu, A., Beroukhim, R., Cibulskis, K., Signoretti, S., *et al.* (2013) Comprehensive molecular characterization of clear cell renal cell carcinoma. *Nature*, **499**(7456): 43–49.
- Croft, D., Mundo, A.F., Haw, R., Milacic, M., Weiser, J., Wu, G., Caudy, M., Garapati, P., Gillespie, M., Kamdar, M.R., *et al.* (2014) The Reactome pathway knowledge-base. *Nucleic Acids Res*, **42**(database issue): D472D477.
- Crunkhorn, S. (2014) Cancer: Predicting synthetic lethal interactions. *Nat Rev Drug Discov*, **13**(11): 812.
- Curtis, C., Shah, S.P., Chin, S.F., Turashvili, G., Rueda, O.M., Dunning, M.J., Speed, D., Lynch, A.G., Samarajiwa, S., Yuan, Y., *et al.* (2012) The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. *Nature*, **486**(7403): 346–352.
- Dai, X., Li, T., Bai, Z., Yang, Y., Liu, X., Zhan, J., and Shi, B. (2015) Breast cancer intrinsic subtype classification, clinical use and future trends. *Am J Cancer Res*, **5**(10): 2929–2943.
- Davierwala, A.P., Haynes, J., Li, Z., Brost, R.L., Robinson, M.D., Yu, L., Mnaimneh, S., Ding, H., Zhu, H., Chen, Y., *et al.* (2005) The synthetic genetic interaction spectrum of essential genes. *Nat Genet*, **37**(10): 1147–1152.

- De Leeuw, W.J., Berx, G., Vos, C.B., Peterse, J.L., Van de Vijver, M.J., Litvinov, S., Van Roy, F., Cornelisse, C.J., and Cleton-Jansen, A.M. (1997) Simultaneous loss of e-cadherin and catenins in invasive lobular breast cancer and lobular carcinoma in situ. *J Pathol*, **183**(4): 404–11.
- Deshpande, R., Asiedu, M.K., Klebig, M., Sutor, S., Kuzmin, E., Nelson, J., Piotrowski, J., Shin, S.H., Yoshida, M., Costanzo, M., *et al.* (2013) A comparative genomic approach for identifying synthetic lethal interactions in human cancer. *Cancer Res*, **73**(20): 6128–36.
- Dickson, D. (1999) Wellcome funds cancer database. *Nature*, **401**(6755): 729.
- Dienstmann, R. and Tabernero, J. (2011) Braf as a target for cancer therapy. *Anticancer Agents Med Chem*, **11**(3): 285–95.
- Dixon, S.J., Andrews, B.J., and Boone, C. (2009) Exploring the conservation of synthetic lethal genetic interaction networks. *Commun Integr Biol*, **2**(2): 78–81.
- Dixon, S.J., Fedyshyn, Y., Koh, J.L., Prasad, T.S., Chahwan, C., Chua, G., Toufighi, K., Baryshnikova, A., Hayles, J., Hoe, K.L., *et al.* (2008) Significant conservation of synthetic lethal genetic interaction networks between distantly related eukaryotes. *Proc Natl Acad Sci U S A*, **105**(43): 16653–8.
- Dorogovtsev, S.N. and Mendes, J.F. (2003) *Evolution of networks: From biological nets to the Internet and WWW*. Oxford University Press, USA.
- Erdős, P. and Rényi, A. (1959) On random graphs I. *Publ Math Debrecen*, **6**: 290–297.
- Erdős, P. and Rényi, A. (1960) On the evolution of random graphs. In *Publ. Math. Inst. Hung. Acad. Sci*, volume 5, 17–61.
- Ezkurdia, I., Juan, D., Rodriguez, J.M., Frankish, A., Diekhans, M., Harrow, J., Vazquez, J., Valencia, A., and Tress, M.L. (2014) Multiple evidence strands suggest that there may be as few as 19 000 human protein-coding genes. *Human Molecular Genetics*, **23**(22): 5866.
- Farmer, H., McCabe, N., Lord, C.J., Tutt, A.N., Johnson, D.A., Richardson, T.B., Santarosa, M., Dillon, K.J., Hickson, I., Knights, C., *et al.* (2005) Targeting the dna repair defect in brca mutant cells as a therapeutic strategy. *Nature*, **434**(7035): 917–21.

- Fece de la Cruz, F., Gapp, B.V., and Nijman, S.M. (2015) Synthetic lethal vulnerabilities of cancer. *Annu Rev Pharmacol Toxicol*, **55**: 513–531.
- Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D.M., Forman, D., and Bray, F. (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. *Int J Cancer*, **136**(5): E359–386.
- Fisher, R.A. (1919) Xv.the correlation between relatives on the supposition of mendelian inheritance. *Earth and Environmental Science Transactions of the Royal Society of Edinburgh*, **52**(02): 399–433.
- Fong, P.C., Boss, D.S., Yap, T.A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O’Connor, M.J., *et al.* (2009) Inhibition of poly(adp-ribose) polymerase in tumors from brca mutation carriers. *N Engl J Med*, **361**(2): 123–34.
- Fong, P.C., Yap, T.A., Boss, D.S., Carden, C.P., Mergui-Roelvink, M., Gourley, C., De Greve, J., Lubinski, J., Shanley, S., Messiou, C., *et al.* (2010) Poly(adp)-ribose polymerase inhibition: frequent durable responses in brca carrier ovarian cancer correlating with platinum-free interval. *J Clin Oncol*, **28**(15): 2512–9.
- Forbes, S.A., Beare, D., Gunasekaran, P., Leung, K., Bindal, N., Boutselakis, H., Ding, M., Bamford, S., Cole, C., Ward, S., *et al.* (2015) COSMIC: exploring the world’s knowledge of somatic mutations in human cancer. *Nucleic Acids Res*, **43**(Database issue): D805–811.
- Fraser, A. (2004) Towards full employment: using rnai to find roles for the redundant. *Oncogene*, **23**(51): 8346–52.
- Futreal, P.A., Coin, L., Marshall, M., Down, T., Hubbard, T., Wooster, R., Rahman, N., and Stratton, M.R. (2004) A census of human cancer genes. *Nat Rev Cancer*, **4**(3): 177–183.
- Futreal, P.A., Kasprzyk, A., Birney, E., Mullikin, J.C., Wooster, R., and Stratton, M.R. (2001) Cancer and genomics. *Nature*, **409**(6822): 850–852.
- Gilbert, W. and Maxam, A. (1973) The nucleotide sequence of the lac operator. *Proceedings of the National Academy of Sciences*, **70**(12): 3581–3584.

- Git, A., Dvinge, H., Salmon-Divon, M., Osborne, M., Kutter, C., Hadfield, J., Bertone, P., and Caldas, C. (2010) Systematic comparison of microarray profiling, real-time PCR, and next-generation sequencing technologies for measuring differential microRNA expression. *RNA*, **16**(5): 991–1006.
- Graziano, F., Humar, B., and Guilford, P. (2003) The role of the e-cadherin gene (*cdh1*) in diffuse gastric cancer susceptibility: from the laboratory to clinical practice. *Annals of Oncology*, **14**(12): 1705–1713.
- Green, R.E., Briggs, A.W., Krause, J., Prufer, K., Burbano, H.A., Siebauer, M., Lachmann, M., and Pääbo, S. (2009) The Neandertal genome and ancient DNA authenticity. *EMBO J*, **28**(17): 2494–2502.
- Güell, O., Sagus, F., and Serrano, M. (2014) Essential plasticity and redundancy of metabolism unveiled by synthetic lethality analysis. *PLoS Comput Biol*, **10**(5): e1003637.
- Guilford, P. (1999) E-cadherin downregulation in cancer: fuel on the fire? *Molecular Medicine Today*, **5**(4): 172 – 177.
- Guilford, P., Hopkins, J., Harraway, J., McLeod, M., McLeod, N., Harawira, P., Taite, H., Scoular, R., Miller, A., and Reeve, A.E. (1998) E-cadherin germline mutations in familial gastric cancer. *Nature*, **392**(6674): 402–5.
- Guilford, P., Humar, B., and Blair, V. (2010) Hereditary diffuse gastric cancer: translation of *cdh1* germline mutations into clinical practice. *Gastric Cancer*, **13**(1): 1–10.
- Guilford, P.J., Hopkins, J.B., Grady, W.M., Markowitz, S.D., Willis, J., Lynch, H., Rajput, A., Wiesner, G.L., Lindor, N.M., Burgart, L.J., *et al.* (1999) E-cadherin germline mutations define an inherited cancer syndrome dominated by diffuse gastric cancer. *Hum Mutat*, **14**(3): 249–55.
- Guo, J., Liu, H., and Zheng, J. (2016) SynLethDB: synthetic lethality database toward discovery of selective and sensitive anticancer drug targets. *Nucleic Acids Res*, **44**(D1): D1011–1017.
- Hall, M., Frank, E., Holmes, G., Pfahringer, B., Reutemann, P., and Witten, I.H. (2009) The weka data mining software: an update. *SIGKDD Explor Newsl*, **11**(1): 10–18.



- Hammerman, P.S., Lawrence, M.S., Voet, D., Jing, R., Cibulskis, K., Sivachenko, A., Stojanov, P., McKenna, A., Lander, E.S., Gabriel, S., *et al.* (2012) Comprehensive genomic characterization of squamous cell lung cancers. *Nature*, **489**(7417): 519–525.
- Han, J.D.J., Bertin, N., Hao, T., Goldberg, D.S., Berriz, G.F., Zhang, L.V., Dupuy, D., Walhout, A.J.M., Cusick, M.E., Roth, F.P., *et al.* (2004) Evidence for dynamically organized modularity in the yeast protein-protein interaction network. *Nature*, **430**(6995): 88–93.
- Hanahan, D. and Weinberg, R.A. (2000) The hallmarks of cancer. *Cell*, **100**(1): 57–70.
- Hanahan, D. and Weinberg, R.A. (2011) Hallmarks of cancer: the next generation. *Cell*, **144**(5): 646–674.
- Hanna, S. (2003) Cancer incidence in new zealand (2003-2007). In D. Forman, D. Bray F Brewster, C. Gombe Mbalawa, B. Kohler, M. Piñeros, E. Steliarova-Foucher, R. Swaminathan, and J. Ferlay (editors), *Cancer Incidence in Five Continents*, volume X, 902–907. International Agency for Research on Cancer, Lyon, France. Electronic version <http://ci5.iarc.fr> Accessed 22/03/2017.
- Heiskanen, M., Bian, X., Swan, D., and Basu, A. (2014) caArray microarray database in the cancer biomedical informatics grid<sup>TM</sup> (caBIG<sup>TM</sup>). *Cancer Research*, **67**(9 Supplement): 3712–3712.
- Heiskanen, M.A. and Aittokallio, T. (2012) Mining high-throughput screens for cancer drug targets-lessons from yeast chemical-genomic profiling and synthetic lethality. *Wiley Interdisciplinary Reviews: Data Mining and Knowledge Discovery*, **2**(3): 263–272.
- Herschkowitz, J.I., Simin, K., Weigman, V.J., Mikaelian, I., Usary, J., Hu, Z., Rasmussen, K.E., Jones, L.P., Assefnia, S., Chandrasekharan, S., *et al.* (2007) Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. *Genome Biol*, **8**(5): R76.
- Hillenmeyer, M.E. (2008) The chemical genomic portrait of yeast: uncovering a phenotype for all genes. *Science*, **320**: 362–365.
- Hoadley, K.A., Yau, C., Wolf, D.M., Cherniack, A.D., Tamborero, D., Ng, S., Leiserson, M.D., Niu, B., McLellan, M.D., Uzunangelov, V., *et al.* (2014) Multiplatform analysis

- of 12 cancer types reveals molecular classification within and across tissues of origin. *Cell*, **158**(4): 929–944.
- Hoehndorf, R., Hardy, N.W., Osumi-Sutherland, D., Tweedie, S., Schofield, P.N., and Gkoutos, G.V. (2013) Systematic analysis of experimental phenotype data reveals gene functions. *PLoS ONE*, **8**(4): e60847.
- Holme, P. and Kim, B.J. (2002) Growing scale-free networks with tunable clustering. *Physical Review E*, **65**(2): 026107.
- Hopkins, A.L. (2008) Network pharmacology: the next paradigm in drug discovery. *Nat Chem Biol*, **4**(11): 682–690.
- Hu, Z., Fan, C., Oh, D.S., Marron, J.S., He, X., Qaqish, B.F., Livasy, C., Carey, L.A., Reynolds, E., Dressler, L., *et al.* (2006) The molecular portraits of breast tumors are conserved across microarray platforms. *BMC Genomics*, **7**: 96.
- Illumina, Inc (Illumina) (2017) Sequencing and array-based solutions for genetic research. <https://www.illumina.com/>. Accessed: 26/03/2017.
- International HapMap 3 Consortium (HapMap) (2003) The International HapMap Project. *Nature*, **426**(6968): 789–796.
- International Human Genome Sequencing Consortium (IHGSC) (2004) Finishing the euchromatic sequence of the human genome. *Nature*, **431**(7011): 931–945.
- Jerby-Arnon, L., Pfitzer, N., Waldman, Y., McGarry, L., James, D., Shanks, E., Seashore-Ludlow, B., Weinstock, A., Geiger, T., Clemons, P., *et al.* (2014) Predicting cancer-specific vulnerability via data-driven detection of synthetic lethality. *Cell*, **158**(5): 1199–1209.
- Joachims, T. (1999) Making large-scale support vector machine learning practical. In S. Bernhard, I. Kropf, J.C.B. Christopher, and J.S. Alexander (editors), *Advances in kernel methods*, 169–184. MIT Press.
- Kaelin, Jr, W. (2005) The concept of synthetic lethality in the context of anticancer therapy. *Nat Rev Cancer*, **5**(9): 689–98.
- Kaelin, Jr, W. (2009) Synthetic lethality: a framework for the development of wiser cancer therapeutics. *Genome Med*, **1**: 99.

- Kandoth, C., Schultz, N., Cherniack, A.D., Akbani, R., Liu, Y., Shen, H., Robertson, A.G., Pashtan, I., Shen, R., Benz, C.C., *et al.* (2013) Integrated genomic characterization of endometrial carcinoma. *Nature*, **497**(7447): 67–73.
- Kawai, J., Shinagawa, A., Shibata, K., Yoshino, M., Itoh, M., Ishii, Y., Arakawa, T., Hara, A., Fukunishi, Y., Konno, H., *et al.* (2001) Functional annotation of a full-length mouse cDNA collection. *Nature*, **409**(6821): 685–690.
- Kelley, R. and Ideker, T. (2005) Systematic interpretation of genetic interactions using protein networks. *Nat Biotech*, **23**(5): 561–566.
- Kozlov, K.N., Gursky, V.V., Kulakovskiy, I.V., and Samsonova, M.G. (2015) Sequence-based model of gap gene regulation network. *BMC Genomics*, **15**(Suppl 12): S6.
- Kranthi, S., Rao, S., and Manimaran, P. (2013) Identification of synthetic lethal pairs in biological systems through network information centrality. *Mol BioSyst*, **9**(8): 2163–2167.
- Lander, E.S. (2011) Initial impact of the sequencing of the human genome. *Nature*, **470**(7333): 187–197.
- Lander, E.S., Linton, L.M., Birren, B., Nusbaum, C., Zody, M.C., Baldwin, J., Devon, K., Dewar, K., Doyle, M., FitzHugh, W., *et al.* (2001) Initial sequencing and analysis of the human genome. *Nature*, **409**(6822): 860–921.
- Laufer, C., Fischer, B., Billmann, M., Huber, W., and Boutros, M. (2013) Mapping genetic interactions in human cancer cells with rnai and multiparametric phenotyping. *Nat Methods*, **10**(5): 427–31.
- Lawrence, M.S., Sougnez, C., Lichtenstein, L., Cibulskis, K., Lander, E., Gabriel, S.B., Getz, G., Ally, A., Balasundaram, M., Birol, I., *et al.* (2015) Comprehensive genomic characterization of head and neck squamous cell carcinomas. *Nature*, **517**(7536): 576–582.
- Le Meur, N. and Gentleman, R. (2008) Modeling synthetic lethality. *Genome Biol*, **9**(9): R135.
- Le Meur, N., Jiang, Z., Liu, T., Mar, J., and Gentleman, R.C. (2014) Slgi: Synthetic lethal genetic interaction. r package version 1.26.0.

- Lee, A.Y., Perreault, R., Harel, S., Boulier, E.L., Suderman, M., Hallett, M., and Jenna, S. (2010a) Searching for signaling balance through the identification of genetic interactors of the rab guanine-nucleotide dissociation inhibitor gdi-1. *PLoS ONE*, **5**(5): e10624.
- Lee, I., Lehner, B., Vavouri, T., Shin, J., Fraser, A.G., and Marcotte, E.M. (2010b) Predicting genetic modifier loci using functional gene networks. *Genome Research*, **20**(8): 1143–1153.
- Lee, I. and Marcotte, E.M. (2009) Effects of functional bias on supervised learning of a gene network model. *Methods Mol Biol*, **541**: 463–75.
- Lee, M.J., Ye, A.S., Gardino, A.K., Heijink, A.M., Sorger, P.K., MacBeath, G., and Yaffe, M.B. (2012) Sequential application of anticancer drugs enhances cell death by rewiring apoptotic signaling networks. *Cell*, **149**(4): 780–94.
- Lehner, B., Crombie, C., Tischler, J., Fortunato, A., and Fraser, A.G. (2006) Systematic mapping of genetic interactions in *caenorhabditis elegans* identifies common modifiers of diverse signaling pathways. *Nat Genet*, **38**(8): 896–903.
- Li, X.J., Mishra, S.K., Wu, M., Zhang, F., and Zheng, J. (2014) Syn-lethality: An integrative knowledge base of synthetic lethality towards discovery of selective anticancer therapies. *Biomed Res Int*, **2014**: 196034.
- Linehan, W.M., Spellman, P.T., Ricketts, C.J., Creighton, C.J., Fei, S.S., Davis, C., Wheeler, D.A., Murray, B.A., Schmidt, L., Vocke, C.D., *et al.* (2016) Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. *N Engl J Med*, **374**(2): 135–145.
- Lokody, I. (2014) Computational modelling: A computational crystal ball. *Nature Reviews Cancer*, **14**(10): 649–649.
- Lord, C.J., Tutt, A.N., and Ashworth, A. (2015) Synthetic lethality and cancer therapy: lessons learned from the development of PARP inhibitors. *Annu Rev Med*, **66**: 455–470.
- Lu, X., Kensche, P.R., Huynen, M.A., and Notebaart, R.A. (2013) Genome evolution predicts genetic interactions in protein complexes and reveals cancer drug targets. *Nat Commun*, **4**: 2124.

- Lu, X., Megchelenbrink, W., Notebaart, R.A., and Huynen, M.A. (2015) Predicting human genetic interactions from cancer genome evolution. *PLoS One*, **10**(5): e0125795.
- Lum, P.Y., Armour, C.D., Stepaniants, S.B., Cavet, G., Wolf, M.K., Butler, J.S., Hinshaw, J.C., Garnier, P., Prestwich, G.D., Leonardson, A., *et al.* (2004) Discovering modes of action for therapeutic compounds using a genome-wide screen of yeast heterozygotes. *Cell*, **116**(1): 121–137.
- Luo, J., Solimini, N.L., and Elledge, S.J. (2009) Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction. *Cell*, **136**(5): 823–837.
- Machado, J., Olivera, C., Carvalh, R., Soares, P., Berx, G., Caldas, C., Sercuca, R., Carneiro, F., and Sorbrinho-Simoes, M. (2001) E-cadherin gene (*cdh1*) promoter methylation as the second hit in sporadic diffuse gastric carcinoma. *Oncogene*, **20**: 1525–1528.
- Masciari, S., Larsson, N., Senz, J., Boyd, N., Kaurah, P., Kandel, M.J., Harris, L.N., Pinheiro, H.C., Troussard, A., Miron, P., *et al.* (2007) Germline e-cadherin mutations in familial lobular breast cancer. *J Med Genet*, **44**(11): 726–31.
- Mattison, J., van der Weyden, L., Hubbard, T., and Adams, D.J. (2009) Cancer gene discovery in mouse and man. *Biochim Biophys Acta*, **1796**(2): 140–161.
- Maxam, A.M. and Gilbert, W. (1977) A new method for sequencing DNA. *Proceedings of the National Academy of Science*, **74**(2): 560–564.
- McCourt, C.M., McArt, D.G., Mills, K., Catherwood, M.A., Maxwell, P., Waugh, D.J., Hamilton, P., O’Sullivan, J.M., and Salto-Tellez, M. (2013) Validation of next generation sequencing technologies in comparison to current diagnostic gold standards for BRAF, EGFR and KRAS mutational analysis. *PLoS ONE*, **8**(7): e69604.
- McLachlan, J., George, A., and Banerjee, S. (2016) The current status of parp inhibitors in ovarian cancer. *Tumori*, **102**(5): 433–440.
- McLendon, R., Friedman, A., Bigner, D., Van Meir, E.G., Brat, D.J., Mastrogianakis, G.M., Olson, J.J., Mikkelsen, T., Lehman, N., Aldape, K., *et al.* (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. *Nature*, **455**(7216): 1061–1068.

- Miles, D.W. (2001) Update on HER-2 as a target for cancer therapy: herceptin in the clinical setting. *Breast Cancer Res*, **3**(6): 380–384.
- Muzny, D.M., Bainbridge, M.N., Chang, K., Dinh, H.H., Drummond, J.A., Fowler, G., Kovar, C.L., Lewis, L.R., Morgan, M.B., Newsham, I.F., *et al.* (2012) Comprehensive molecular characterization of human colon and rectal cancer. *Nature*, **487**(7407): 330–337.
- Noonan, J.P., Coop, G., Kudaravalli, S., Smith, D., Krause, J., Alessi, J., Chen, F., Platt, D., Pääbo, S., Pritchard, J.K., *et al.* (2006) Sequencing and analysis of Neanderthal genomic DNA. *Science*, **314**(5802): 1113–1118.
- Oliveira, C., Senz, J., Kaurah, P., Pinheiro, H., Sanges, R., Haegert, A., Corso, G., Schouten, J., Fitzgerald, R., Vogelsang, H., *et al.* (2009) Germline *cdh1* deletions in hereditary diffuse gastric cancer families. *Human Molecular Genetics*, **18**(9): 1545–1555.
- Oliveira, C., Seruca, R., Hoogerbrugge, N., Ligtenberg, M., and Carneiro, F. (2013) Clinical utility gene card for: Hereditary diffuse gastric cancer (HDGC). *Eur J Hum Genet*, **21**(8).
- Oxford Nanopore Technologies (Nanopore) (2017) Oxford Nanopore Technologies. <https://nanoporetech.com/>. Accessed: 27/03/2017.
- PacBio (PacBio) (2017) Pacific Biosciences. <http://www.pacb.com/>. Accessed: 27/03/2017.
- Pandey, G., Zhang, B., Chang, A.N., Myers, C.L., Zhu, J., Kumar, V., and Schadt, E.E. (2010) An integrative multi-network and multi-classifier approach to predict genetic interactions. *PLoS Comput Biol*, **6**(9).
- Parker, J., Mullins, M., Cheung, M., Leung, S., Voduc, D., Vickery, T., Davies, S., Fauron, C., He, X., Hu, Z., *et al.* (2009) Supervised risk predictor of breast cancer based on intrinsic subtypes. *Journal of Clinical Oncology*, **27**(8): 1160–1167.
- Peltonen, L. and McKusick, V.A. (2001) Genomics and medicine. Dissecting human disease in the postgenomic era. *Science*, **291**(5507): 1224–1229.
- Pereira, B., Chin, S.F., Rueda, O.M., Vollan, H.K., Provenzano, E., Bardwell, H.A., Pugh, M., Jones, L., Russell, R., Sammut, S.J., *et al.* (2016) Erratum: The somatic

- mutation profiles of 2,433 breast cancers refine their genomic and transcriptomic landscapes. *Nat Commun*, **7**: 11908.
- Perou, C.M., Sørlie, T., Eisen, M.B., van de Rijn, M., Jeffrey, S.S., Rees, C.A., Pollack, J.R., Ross, D.T., Johnsen, H., Akslen, L.A., *et al.* (2000) Molecular portraits of human breast tumours. *Nature*, **406**(6797): 747–752.
- Pleasance, E.D., Cheetham, R.K., Stephens, P.J., McBride, D.J., Humphray, S.J., Greenman, C.D., Varela, I., Lin, M.L., Ordóñez, G.R., Bignell, G.R., *et al.* (2010) A comprehensive catalogue of somatic mutations from a human cancer genome. *Nature*, **463**(7278): 191–196.
- Polyak, K. and Weinberg, R.A. (2009) Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. *Nat Rev Cancer*, **9**(4): 265–73.
- Prahalad, A., Sun, C., Huang, S., Di Nicolantonio, F., Salazar, R., Zecchin, D., Beijersbergen, R.L., Bardelli, A., and Bernards, R. (2012) Unresponsiveness of colon cancer to braf(v600e) inhibition through feedback activation of egfr. *Nature*, **483**(7387): 100–3.
- Quantum Biosystems Inc. (Quantum Biosystems) (2017) Quantum Biosystems, . <http://www.quantumbiosystems.com/>. Accessed: 27/03/2017.
- Ravnan, M.C. and Matalaka, M.S. (2012) Vemurafenib in patients with braf v600e mutation-positive advanced melanoma. *Clin Ther*, **34**(7): 1474–86.
- Robin, J.D., Ludlow, A.T., LaRanger, R., Wright, W.E., and Shay, J.W. (2016) Comparison of DNA Quantification Methods for Next Generation Sequencing. *Sci Rep*, **6**: 24067.
- Roguev, A., Bandyopadhyay, S., Zofall, M., Zhang, K., Fischer, T., Collins, S.R., Qu, H., Shales, M., Park, H.O., Hayles, J., *et al.* (2008) Conservation and rewiring of functional modules revealed by an epistasis map in fission yeast. *Science*, **322**(5900): 405–10.
- Rothberg, J.M. and Leamon, J.H. (2008) The development and impact of 454 sequencing. *Nat Biotechnol*, **26**(10): 1117–1124.
- Rung, J. and Brazma, A. (2013) Reuse of public genome-wide gene expression data. *Nat Rev Genet*, **14**(2): 89–99.

- Rustici, G., Kolesnikov, N., Brandizi, M., Burdett, T., Dylag, M., Emam, I., Farne, A., Hastings, E., Ison, J., Keays, M., *et al.* (2013) ArrayExpress update—trends in database growth and links to data analysis tools. *Nucleic Acids Res*, **41**(Database issue): D987–990.
- Ryan, C., Lord, C., and Ashworth, A. (2014) Daisy: Picking synthetic lethals from cancer genomes. *Cancer Cell*, **26**(3): 306–308.
- Sander, J.D. and Joung, J.K. (2014) Crispr-cas systems for editing, regulating and targeting genomes. *Nat Biotechnol*, **32**(4): 347–55.
- Sanger, F. and Coulson, A. (1975) A rapid method for determining sequences in dna by primed synthesis with dna polymerase. *Journal of Molecular Biology*, **94**(3): 441 – 448.
- Scheuer, L., Kauff, N., Robson, M., Kelly, B., Barakat, R., Satagopan, J., Ellis, N., Hensley, M., Boyd, J., Borgen, P., *et al.* (2002) Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers. *J Clin Oncol*, **20**(5): 1260–1268.
- Semb, H. and Christofori, G. (1998) The tumor-suppressor function of e-cadherin. *Am J Hum Genet*, **63**(6): 1588–93.
- Sørlie, T., Perou, C.M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., Hastie, T., Eisen, M.B., van de Rijn, M., Jeffrey, S.S., *et al.* (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. *Proc Natl Acad Sci USA*, **98**(19): 10869–10874.
- Stratton, M.R., Campbell, P.J., and Futreal, P.A. (2009) The cancer genome. *Nature*, **458**(7239): 719–724.
- Ström, C. and Helleday, T. (2012) Strategies for the use of poly(adenosine diphosphate ribose) polymerase (parp) inhibitors in cancer therapy. *Biomolecules*, **2**(4): 635–649.
- Sun, C., Wang, L., Huang, S., Heynen, G.J.J.E., Prahallad, A., Robert, C., Haanen, J., Blank, C., Wesseling, J., Willems, S.M., *et al.* (2014) Reversible and adaptive resistance to braf(v600e) inhibition in melanoma. *Nature*, **508**(7494): 118–122.
- Taylor, I.W., Linding, R., Warde-Farley, D., Liu, Y., Pesquita, C., Faria, D., Bull, S., Pawson, T., Morris, Q., and Wrana, J.L. (2009) Dynamic modularity in protein



- interaction networks predicts breast cancer outcome. *Nat Biotechnol*, **27**(2): 199–204.
- Telford, B.J., Chen, A., Beetham, H., Frick, J., Brew, T.P., Gould, C.M., Single, A., Godwin, T., Simpson, K.J., and Guilford, P. (2015) Synthetic lethal screens identify vulnerabilities in gpcr signalling and cytoskeletal organization in e-cadherin-deficient cells. *Mol Cancer Ther*, **14**(5): 1213–1223.
- The 1000 Genomes Project Consortium (1000 Genomes) (2010) A map of human genome variation from population-scale sequencing. *Nature*, **467**(7319): 1061–1073.
- The Cancer Genome Atlas Research Network (TCGA) (2012) Comprehensive molecular portraits of human breast tumours. *Nature*, **490**(7418): 61–70.
- The Cancer Genome Atlas Research Network (TCGA) (2017) The Cancer Genome Atlas Project. <https://cancergenome.nih.gov/>. Accessed: 26/03/2017.
- The Cancer Society of New Zealand (Cancer Society of NZ) (2017) What is cancer? <https://otago-southland.cancernz.org.nz/en/cancer-information/other-links/what-is-cancer-3/>. Accessed: 22/03/2017.
- The Catalogue Of Somatic Mutations In Cancer (COSMIC) (2016) Cosmic: The catalogue of somatic mutations in cancer. <http://cancer.sanger.ac.uk/cosmic>. Release 79 (23/08/2016), Accessed: 05/02/2017.
- The ENCODE Project Consortium (ENCODE) (2004) The ENCODE (ENCyclopedia Of DNA Elements) Project. *Science*, **306**(5696): 636–640.
- The International Cancer Genome Consortium (ICGC) (2017) ICGC Data Portal. <https://dcc.icgc.org/>. Accessed: 26/03/2017.
- Thermo Fisher Scientific (ThermoFisher) (2017a) Ion Proton System for Next Generation Sequencing. <https://www.thermofisher.com>. Accessed: 27/03/2017.
- Thermo Fisher Scientific (ThermoFisher) (2017b) SOLiD Next Generation Sequencing. <https://www.thermofisher.com>. Accessed: 27/03/2017.
- The National Cancer Institute (NCI) (2015) The genetics of cancer. <https://www.cancer.gov/about-cancer/causes-prevention/genetics>. Published: 22/04/2015, Accessed: 22/03/2017.

- The Pharmaceutical Management Agency (PHARMAC) (2016) Approval of multi-product funding proposal with roche.
- Tiong, K.L., Chang, K.C., Yeh, K.T., Liu, T.Y., Wu, J.H., Hsieh, P.H., Lin, S.H., Lai, W.Y., Hsu, Y.C., Chen, J.Y., *et al.* (2014) Csnk1e/ctnnb1 are synthetic lethal to tp53 in colorectal cancer and are markers for prognosis. *Neoplasia*, **16**(5): 441–50.
- Tischler, J., Lehner, B., and Fraser, A.G. (2008) Evolutionary plasticity of genetic interaction networks. *Nat Genet*, **40**(4): 390–391.
- Tomasetti, C. and Vogelstein, B. (2015) Cancer etiology. Variation in cancer risk among tissues can be explained by the number of stem cell divisions. *Science*, **347**(6217): 78–81.
- Tong, A.H., Evangelista, M., Parsons, A.B., Xu, H., Bader, G.D., Page, N., Robinson, M., Raghibizadeh, S., Hogue, C.W., Bussey, H., *et al.* (2001) Systematic genetic analysis with ordered arrays of yeast deletion mutants. *Science*, **294**(5550): 2364–8.
- Tong, A.H., Lesage, G., Bader, G.D., Ding, H., Xu, H., Xin, X., Young, J., Berriz, G.F., Brost, R.L., Chang, M., *et al.* (2004) Global mapping of the yeast genetic interaction network. *Science*, **303**(5659): 808–13.
- Travers, J. and Milgram, S. (1969) An experimental study of the small world problem. *Sociometry*, **32**(4): 425–443.
- Tsai, H.C., Li, H., Van Neste, L., Cai, Y., Robert, C., Rassool, F.V., Shin, J.J., Harbom, K.M., Beaty, R., Pappou, E., *et al.* (2012) Transient low doses of dna-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. *Cancer Cell*, **21**(3): 430–46.
- Tutt, A., Robson, M., Garber, J.E., Domchek, S.M., Audeh, M.W., Weitzel, J.N., Friedlander, M., Arun, B., Loman, N., Schmutzler, R.K., *et al.* (2010) Oral poly(adp-ribose) polymerase inhibitor olaparib in patients with brca1 or brca2 mutations and advanced breast cancer: a proof-of-concept trial. *Lancet*, **376**(9737): 235–44.
- van der Meer, R., Song, H.Y., Park, S.H., Abdulkadir, S.A., and Roh, M. (2014) RNAi screen identifies a synthetic lethal interaction between PIM1 overexpression and PLK1 inhibition. *Clinical Cancer Research*, **20**(12): 3211–3221.
- van Steen, K. (2012) Travelling the world of genegene interactions. *Briefings in Bioinformatics*, **13**(1): 1–19.

- van Steen, M. (2010) *Graph Theory and Complex Networks: An Introduction*. Maarten van Steen, VU Amsterdam.
- Vapnik, V.N. (1995) *The nature of statistical learning theory*. Springer-Verlag New York, Inc.
- Vargas, J.J., Gusella, G., Najfeld, V., Klotman, M., and Cara, A. (2004) Novel integrase-defective lentiviral episomal vectors for gene transfer. *Hum Gene Ther*, **15**: 361–372.
- Venter, J.C., Adams, M.D., Myers, E.W., Li, P.W., Mural, R.J., Sutton, G.G., Smith, H.O., Yandell, M., Evans, C.A., Holt, R.A., *et al.* (2001) The sequence of the human genome. *Science*, **291**(5507): 1304–1351.
- Vizeacoumar, F.J., Arnold, R., Vizeacoumar, F.S., Chandrashekhar, M., Buzina, A., Young, J.T., Kwan, J.H., Sayad, A., Mero, P., Lawo, S., *et al.* (2013) A negative genetic interaction map in isogenic cancer cell lines reveals cancer cell vulnerabilities. *Mol Syst Biol*, **9**: 696.
- Vogelstein, B., Papadopoulos, N., Velculescu, V.E., Zhou, S., Diaz, L.A., and Kinzler, K.W. (2013) Cancer genome landscapes. *Science*, **339**(6127): 1546–1558.
- Vos, C.B., Cleton-Jansen, A.M., Berx, G., de Leeuw, W.J., ter Haar, N.T., van Roy, F., Cornelisse, C.J., Peterse, J.L., and van de Vijver, M.J. (1997) E-cadherin inactivation in lobular carcinoma in situ of the breast: an early event in tumorigenesis. *Br J Cancer*, **76**(9): 1131–3.
- Wadman, M. and Watson, J. (2008) James Watson’s genome sequenced at high speed. *Nature*, **452**(7189): 788.
- Wang, X. and Simon, R. (2013) Identification of potential synthetic lethal genes to p53 using a computational biology approach. *BMC Medical Genomics*, **6**(1): 30.
- Wappett, M. (2014) Bisep: Toolkit to identify candidate synthetic lethality. r package version 2.0.
- Wappett, M., Dulak, A., Yang, Z.R., Al-Watban, A., Bradford, J.R., and Dry, J.R. (2016) Multi-omic measurement of mutually exclusive loss-of-function enriches for candidate synthetic lethal gene pairs. *BMC Genomics*, **17**: 65.

- Watts, D.J. and Strogatz, S.H. (1998) Collective dynamics of 'small-world' networks. *Nature*, **393**(6684): 440–2.
- Weinstein, I.B. (2000) Disorders in cell circuitry during multistage carcinogenesis: the role of homeostasis. *Carcinogenesis*, **21**(5): 857–864.
- Weinstein, J.N., Akbani, R., Broom, B.M., Wang, W., Verhaak, R.G., McConkey, D., Lerner, S., Morgan, M., Creighton, C.J., Smith, C., *et al.* (2014) Comprehensive molecular characterization of urothelial bladder carcinoma. *Nature*, **507**(7492): 315–322.
- Weinstein, J.N., Collisson, E.A., Mills, G.B., Shaw, K.R., Ozenberger, B.A., Ellrott, K., Shmulevich, I., Sander, C., Stuart, J.M., Chang, K., *et al.* (2013) The Cancer Genome Atlas Pan-Cancer analysis project. *Nat Genet*, **45**(10): 1113–1120.
- Wheeler, D.A., Srinivasan, M., Egholm, M., Shen, Y., Chen, L., McGuire, A., He, W., Chen, Y.J., Makhijani, V., Roth, G.T., *et al.* (2008) The complete genome of an individual by massively parallel DNA sequencing. *Nature*, **452**(7189): 872–876.
- Wong, S.L., Zhang, L.V., Tong, A.H.Y., Li, Z., Goldberg, D.S., King, O.D., Lesage, G., Vidal, M., Andrews, B., Bussey, H., *et al.* (2004) Combining biological networks to predict genetic interactions. *Proceedings of the National Academy of Sciences of the United States of America*, **101**(44): 15682–15687.
- World Health Organization (WHO) (2017) Fact sheet: Cancer. <http://www.who.int/mediacentre/factsheets/fs297/en/>. Updated February 2017, Accessed: 22/03/2017.
- Wu, M., Li, X., Zhang, F., Li, X., Kwoh, C.K., and Zheng, J. (2014) In silico prediction of synthetic lethality by meta-analysis of genetic interactions, functions, and pathways in yeast and human cancer. *Cancer Inform*, **13**(Suppl 3): 71–80.
- Zhang, F., Wu, M., Li, X.J., Li, X.L., Kwoh, C.K., and Zheng, J. (2015) Predicting essential genes and synthetic lethality via influence propagation in signaling pathways of cancer cell fates. *J Bioinform Comput Biol*, **13**(3): 1541002.
- Zhang, J., Baran, J., Cros, A., Guberman, J.M., Haider, S., Hsu, J., Liang, Y., Rivkin, E., Wang, J., Whitty, B., *et al.* (2011) International cancer genome consortium data portala one-stop shop for cancer genomics data. *Database: The Journal of Biological Databases and Curation*, **2011**: bar026.

Zhong, W. and Sternberg, P.W. (2006) Genome-wide prediction of *c. elegans* genetic interactions. *Science*, **311**(5766): 1481–1484.